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ABSTRACT 
 
Streptococcus pyogenes (Group A Sreptococcus or GAS) results in a variety of 
human disease including bacterial pharyngitis.  Repeated GAS pharyngitis episodes,  
through the mechanism of molcular mimicry, may lead to acute rheumatic fever and 
a further sequella, rheumatic heart disease (RHD). In South Africa, 23.5 new cases 
of RHD/100,000 per annum have been estimated, being among the highest in the 
world;  yet only few aspect of GAS diseases have been documented.  This study 
invesitgated pharyngeal isolates from children in Cape Town, in an effort to 
contribute to the pathogenesis of GAS pahryngitis, were investigated. 
 
The M-protein sequence typing (emm typing) techniques as well as restriction 
fragment length polymorphism were used to study the M-proteins (emm types) 
circulating among Cape Town children. Sequence analysis was also performed on 
the conserved region of the M protein for possible vaccine targets. A multiplex PCR 
assay was also optimised to study eight streptococcal pyrogenic exotoxins. 
 
 A total of 35 different emm types and subtypes from 143 pharyngeal GAS isolates 
were identified, emm48.1 (12%) being the dominant emm type. RFLP revealed 
restriction profiles distinct to individual emm types. Sequence analyses of the 
conserved region of the M-protein reveal predominantly J14 and J14.1 vaccine 
targets while the multiplex PCR detected SAg profiles that were distributed across 
emm types. 
 
This study present the first laboratory data conducted in a South African setting. 
Following  emm typing, the experimental 26-valent GAS vaccine coverage was 
estimated at 51.7%, among the lowest compared to 85% coverage anticipated in 
developed countries such as the US and Canada. However, conserved region of the 
M-protein harboured predominately J14 and J14.1 sequences which are potential 
vaccine candidates conserved across GAS strains. Data on the extents of GAS 
diseases in South Africa are still limited hence more studies are essential in order to 
enhance understanding of these diseases and the vaccine design that will prove 
effective in preventing RHD.  
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ABBREVIATIONS 
ºC                                degrees celsius  
ARD                           acute respiratory disease 
ARF                            acute rheumatic fever 
bp                                base pair 
BSA                            bovine serum albumin  
CDC                            Centers for Disease Control and Prevention 
GAS                            group A streptococcus 
MEME                        multiple em motif elicitation  
MHC                          major histocompatibility complex 
MLST                         multilocus sequence typing 
NEB                           New England Biolabs   
NF                              necrotizing fasciitis 
PCR                            polymerase chain reaction 
PFGE                          pulsed-field gel electrophoresis 
RFLP                          restriction fragment length polymorphism  
RHD                           rheumatic heart disease 
SAg,                           superantigen(s) 
SPE                             streptococcal pyrogenic exotoxin  
SARS                          severe acute respiratory syndrome 
SMEZ                         streptococcal mitogenic exotoxin Z 
SPA                            streptococcal protective antigen 
SSA                             streptococcal superantigen A 
SSTI                            severe skin and soft tissue infections  
STSS                          streptococcal toxic shock syndrome 
UAE                           United Arab Emirates  
USA                            United States of America 
WHO                          World Health Organization 
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Chapter One: Literature review 
 
Literature review 
 
1.1   Streptococcus pyogenes 
1.1.1 Bacteriology of Streptococcus pyogenes  
The genus Streptococcus comprises gram-positive, catalase-negative, oval or coccoid 
cells organised in pairs and chains hence the name “Streptococcus” [1].  
Streptococcus pyogenes is a facultative anaerobe that grows optimally in the 
presence of media supplemented with blood.  The haemoglobin-haptoglobin 
complex, hemoglobin, myoglobin, heme-albumin and catalase present in blood are 
sources of iron for optimum growth.  This bacterial pathogen causes a wide array of 
clinically important infections such as pharyngitis, scarlet fever, impetigo, 
streptococcal toxic shock syndrome (STSS) as well as the post streptococcal diseases 
such as acute rheumatic fever (ARF) and rheumatic heart disease (RHD).   
 
Streptococci were identified as early as 1874 from patients with cases of erysipelas 
and wound infection by Christian Albert Theodor Billroth [1], followed by 
demonstration of the organism in blood from patients with puerperal sepsis in 1879 
by Pasteur [1].  In 1884, Rosenbach named the organism Streptococcus pyogenes, 
literally meaning pus forming chained round-shaped bacteria [1]. 
 
During the 1920s, S. pyogenes were classified using serological methods [2].  In 
1924 Hitchcock identified a crude streptococcal extract that reacted to antibacterial 
sera [4].  In experiments following the discovery by Hitchcock, Lancefield 
discovered that antibacterial sera were homologous against streptococcal 
haemolytica extracts [7].  The extracts were then classified as protein (M protein) in 
nature following precipitation with dilute alcohol, acetic acid, picric acid and 
digestion by trypsin [6].  To date, the M protein remains the basis of GAS strain 
differentiation [8]. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
5 | P a g e  
 
Investigation of scarlatinal streptococci revealed S. pyogenes isolates were not 
uniform in their serological characteristics [2], hence in 1932, Dr Rebecca Lancefield 
devised a serological method for characterising S. pyogenes using a precipitin test 
which classified streptococci into group A to E based on specific polysaccharides 
present on the cell wall [3].  The basis of this classification is on carbohydrate C, 
which was initially identified in isolates from animals [4] leading to investigation 
whether a similar carbohydrate existed on strains of human origin [5-7].  Anti- 
carbohydrate-C precipitin reactions showed similar titers with antiserum prepared 
against bacteria sharing similarities in their reaction [3].  Group A streptococci 
(GAS) are within the scope of this thesis hence will be the main focus of discussion.  
 
1.1.2 Virulence of GAS 
Streptococcus pyogenes has diverse virulence factors employing four main 
mechanisms; antiphagocytosis, adherence, colonisation and toxin production [8].  
One of the primary human defence mechanisms involves phagocytosis, destruction 
and clearance of foreign invasion by polymorphonuclear leucocytes [8].    
 
Group A streptococci avoid/bypass this defence mechanism through the 
antiphagocytosis mechanism.  The M-protein is extracellular (Figure 1-1), a major 
virulence factor of GAS, a central focus in epidemiological studies and the main 
determinant of M-protein based vaccine coverage [8-11].  M-protein is encoded by 
the emm genes clustered at the vir locus of the chromosome [10].  The antiphagocytic 
effect of the M-protein, the major virulence property, is achieved through 
interference with opsonisation via the alternative complement pathway [12].  Binding 
of M-protein to complement control factors and other host proteins prevents 
activation of the alternate complement pathway thus protecting the bacteria from host 
phagocytosis by polymorphonuclear leukocytes [8, 12].  The M-proteins also bind to 
the Fc region of IgG to evade host phagocytosis [13, 14].  Group A streptococci 
treated with peptic digestion, known for removing the M-protein without distorting 
the integrity of the bacterial morphology, resulted in loss of serological response and 
function of the M-protein activities [12].  These observation were backed by 
resistance of M-protein positive strains exposed to fresh human blood, supporting the 
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hypothesis that the M-protein function in retarding the complement receptors, 
leading to resistance to opsonisation [12].  Another antiphagocytotic effect of GAS is 
achieved through a capsule comprising hyaluronic acid [15].  Encapsulated GAS 
resists phagocytosis while those lacking the capsule are susceptible to phagocytosis 
[15]. 
 
 
                        Figure 1-1.  The M-protein structure. Adopted from [16]. 
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Group A Streptococci adhere to host epithelial cells prior to colonisation and 
internalisation [17].  Adhesins present on GAS include; pili, lipoteichoic acid, M-
protein and fibronectin binding protein [18].  Streptococcal pili have been shown to 
play a role as adhesins in GAS infections [19, 20].  Lipoteichoic acid adheres to 
fibronectin on human buccal epithelial cell [18].  Anti-lipoteichoic acid serum blocks 
colonization and infection of upper respiratory tract in mice [18].  The M-protein 
adheres to Hep-2 cells in tissue culture [21] and skin keratinocytes [22] while 
fibronectin binding protein such as protein F1 (streptococcal binding protein1) 
adheres to cutaneous Langerhans cells [23].   
Colonisation is achieved by factors that evade immunoglobulins and the complement 
cascade [18].  Replication and production of cytolytic toxins may increase in the face 
of a good nutrient supply resulting in dominance over normal flora [18].  C5a 
peptidase produced by GAS inactivates C5a, a component of the complement 
pathway, minimising the influx of neutrophils thus increasing survival [18].   
 
Among extracellular components, two haemolysins; streptolysin O and streptolysin 
S, play a crucial role in the pathogenesis of GAS [8].  Streptolysin O, a conserved 
pore-forming cytolysin, is ineffective in the presence of oxygen, lethal to 
erythrocytes and toxic to polymorphonuclear leukocytes, platelets, tissue-culture and 
lysosomes [8].  Similarly, streptolysin S is produced during growth in presence of 
serum albumin, alpha-lipoprotein and ribonucleic acid. Similarly to streptolysin O, 
streptolysin S (which is not affected by oxygen) has a destructive effect on 
polymorphonuclear leukocytes, platelets, tissue-culture cells and lysosomes but its 
activities can be affected by the presence of serum lipoproteins and phospholipids 
[8].  
 
1.1.3 Streptococcal pyrogenic superantigens 
The most studied superantigens (SAgs) are those seen in S. pyogenes and 
Staphylococcus aureus [24-27], although other microorganisms such as 
Streptococcus dysgalactiae, Mycoplasma arthritidis and Yersinia pseudotuberculosis 
also possess SAg activities.  Superantigens are major virulent factors of GAS.  They 
are extracellular protein toxins that are pyrogenic, increase host susceptibility to 
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endotoxic shock, suppress immunoglobulin production and have mitogenic activity 
for specific T-cell subsets [28].  Under normal circumstances, other antigens, when 
detected by the host immune system, are presented by means of antigen presenting 
cells on major histocompatibility complex (MHC) class II which results in induction 
of T-cell receptors.  However, this is not the case with SAg which bypass antigen 
presenting cells and interact directly with MHC class II resulting in abnormal influx 
of T-cells [29], followed by over-secretion of pro-inflammatory cytokines (IFN-γ and 
lymphotoxin-α) and interleukins resulting in a high risk of developing STSS, multi-
organ failure, acidosis and organ hypoperfusion [29]. 
 
There are eleven know streptococcal pyrogenic exotoxin (SPE); SPEA, SPEC, 
SPEG, SPEH, SPEI, SPEJ, SPEK, SPEL, SPEM, streptococcal mitogenic exotoxin Z 
(SMEZ) and streptococcal superantigen A (SSA) [30].  Some of these SAgs have 
been implicated in GAS diseases such as scarlet fever, STSS and ARF.  The genes 
coding speA and speC have both been associated with scarlet fever and STSS [29, 
31-33], while speL and speM have been identified from ARF patients, suggesting 
their participation in the host-pathogen interactions [34].  The streptococcal 
mitogenic exotoxin is a major immunological active agent and has also been 
associated with STSS [35].  Two toxins, SPEB and SPEF, initially classified as 
legitimate SAg, possess no SAg activities. SpeB codes for streptococcal extracellular 
cysteine proteinase while speF is identical to streptococcal DNase B [29].  Evidence 
of the involvement of SPEF in infected tissues (cellulitis, fasciitis and necrotising 
fasciitis) has also emerged [36]. 
 
Some SAg are chromosomally located while others are located on extrachromosomal 
elements such as phages or plasmids. [27, 30, 37, 38].  With the emergence of whole 
genome sequences of GAS, comes striking evidence of the presence and absence of 
genes coding SAg.  This sequence based evidence, together with frequent detection 
of up to 100% of SAg genes suggests the presence of some of the SAg genes in the 
chromosomes [39-41].  Chromosomally implicated SAgs genes are speG, speJ and 
smeZ.  The chromosomally coded SAg genes should be detectable in all the isolates 
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investigated, however, a 100% detection rate has not been achieved in all the studies 
[30, 37, 42], raising some doubt about the chromosomal location of these genes.  
 
The surge in streptococcal diseases in 1980s mounted speculation of the involvement 
of SAg [42], with the increase largely noticed in invasive diseases such as scarlet 
fever and STSS [34].  However recent studies show no correlation between the 
presence of SAg  and invasive versus non-invasive diseases [37, 41, 43], although 
one study characterised two pyrogenic toxins (SPEL and SPEM) associated with 
ARF [34].  The SAg, speL and speM, were isolated from thirty isolates associated 
with ARF outbreaks in the Salt Lake City, Utah, USA [44]. 
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1.2   Molecular epidemiology of GAS  
1.2.1 emm typing 
The classical serological method devised by Lancefield initiated a platform for 
epidemiological studies of S. pyogenes [3].  More recently, with the advances in 
molecular biology, a sequence based method, emm typing, has been introduced and 
widely used in epidemiological studies of GAS [10].  The N-terminus of the M-
protein is hypervariable (Figure 1-1) and differences in the DNA sequences of this 
region form the basis for the differentiation of the M-proteins, often referred as 
“emm” type.  A particular emm type number is assigned to a sequence beginning with 
the three letters “emm” followed by a number e.g. emm1.  Differences in the 5’ 
region of a particular type determines the subtype e.g. emm1.1.  The emm typing 
assay has been accepted as the most convenient and reliable method of strain typing 
and is now the gold standard in epidemiological studies of GAS [9, 10].  With more 
than 220 emm types documented, GAS isolates can easily be compared to known 
sequences that are catalogued by the Centre for Disease Control and Prevention 
(CDC) [45].  The emm typing technique will be further elaborated in Chapter Two. 
 
1.2.2 Prevalence of emm types 
The emm types circulating among the South African population are unknown. This is 
due to lack of molecular epidemiological studies of GAS.  However, extensive 
review of studies and reports on global distribution of emm types shows similarities 
in the distribution of emm types in developed countries while on the other hand, 
developing countries depict differences in prevalent emm types [11].  Table 1-1 
illustrates a summary of recent emm studies from different continents.  The data from 
Table 1-1 as well as previous report on global distribution of emm types [11], show 
the geographical differences between developed and developing countries.  Inter-
continental similarities among the most prevalent emm types can be observed in 
developed countries while there are differences among the most prevalent emm types 
from developing countries (Table 1-1) [11].  Three studies conducted in the African 
continent (two from Ethiopia and one from Tunisia) revealed differences among five 
most prevalent types. Similarly, results from studies in Asia and South America have 
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shown variations in the “top five” emm types as shown in Table 1-1.  However, 
North America and Europe share predominant emm types. 
 
Table 1-1.  Summary of recent emm typing studies from five continents 
Continent Country Year n No. of  
emm 
types 
Prevalent emm types  
(Descending order of 
prevalence) 
Ref 
A
fr
ic
a
 
Ethiopia 2006 82 43 39.2, 5.48, st62
a
, 29.2
a
, 
st463
a
  
[46] 
Ethiopia 2005 217 78 12, 74, st62, 1, 25 [47] 
Tunisia 2011 103 38 118, 42, 1, st432, 28 [48] 
       
A
si
a
 
China 2011 185 13 12, 1, 22, st1815, 6
a
, 102
a
 [49] 
China 2008 145 5 1, 12, 4, 22, st5240 [32] 
China 
(Taiwan) 
2009 830 21 1, 4, 12, 6, stIL103 [50] 
Fiji 2009 535 67 70, 33, 25, 11
a
, 93, 69 [51] 
Fiji 2009 55 38 100, 76, 11, 33, 106 [52] 
India 2008 34 22 49, 82, 74, 71a, 118a, 121a, 
105
a
 
[53] 
Japan 2002 316 19 12, 28, 1, 4, 13 [54] 
Lebanon 2011 103 33 1, 22, 28, 88, 4 [55] 
UAE 2010 38 25 st3211, 89, 75, st4695, st75  [56] 
       
E
u
r
o
p
e
 
Austria 2006 140 25 1, 4, 12, 28, 77 [57] 
Denmark 2005 201 27 1, 28, 12, 6, 4 [41] 
Germany 2001 216 17 1, 12, 3, 28, 4 [58] 
Italy  2007 207 32 1, 12, 3, 4, 18 [59] 
Italy 2001 114 22 12, 89, 4
a
, 1
a
, 29, 6
a
, 77
a
 [60] 
Norway 2008 101 19 28, 12, 87, 4, 89 [61] 
Romania 2008 147 19 1, 81, 76, 49, 78 [62] 
Spain 2010 673 25 6, 4, 28, 12
a
, 11
a
, 1  [63] 
Spain 2006 126 29 1, 3, 4, 12, 28 [37] 
Strept-
EURO 
program 
2009 4353 104 1, 28, 3, 89, 87 [64] 
       
       
 Mexico 2003 282 27 1, 12, 75, 3, 2, 6 [65] 
 Mexico 2002 40 5 2, 12, 1, 22, 89 [66] 
N
o
r
th
 
A
m
er
ic
a
 US 2009 7040 56 1, 12, 28, 4, 3,  [67] 
Canada 2009 1434 33 12, 1, 28, 4, 3,  [67] 
US (Hawaii) 2009 1482 93 1, 12, 28, 4,22 [68] 
       
S
o
u
th
 
A
m
e
r
ic
a
 Brazil 2006 128 48 53, 22,49, 58, 83, 8 [69] 
a:  similar number of isolate;  n, sample size 
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1.2.3 Other molecular methods used to study the M-protein 
Depending on the question investigators are trying to address in disease outbreaks or 
epidemiological studies, different molecular methods are used to compare bacterial 
strains with either local or global strains.  Frequently used epityping or strain 
fingerprinting assays in GAS studies include pulse-field gel electrophoresis (PFGE), 
restriction fragment length polymorphism (RFLP) and multilocus sequence typing 
(MLST) [55, 70, 71].  
 
In the context of local disease outbreaks, PFGE is considered as the gold standard 
[72].  This assay is second in a series of development of molecular typing techniques 
introduced in 1980s [73] and has since been widely used to study bacterial strains in 
hospital outbreaks.  The principle of PFGE is based on DNA finger printing achieved 
by digesting the whole genome with restriction enzyme, separation of DNA 
fragments on agarose gel with alternating electric field and analysing the DNA 
fingerprint with dedicated software [72].  In GAS studies, PFGE has been used to 
investigate genetic relatedness and disease outbreaks [50, 55, 74-76] depicting 
discriminatory power to distinguish and relate GAS strains [55].  
 
Multilocus sequence typing is a sequence based typing assay, highly effective and 
allows unambiguous characterisation of bacterial strain in global epidemiology [77].  
This assay involves sequencing internal fragments of seven housekeeping genes; 
each sequence is assigned an allelic profile which defines a sequence type.  Large 
numbers of alleles from the seven housekeeping genes provide the ability to 
distinguish different allelic profiles.  A database has been developed for the allelic 
profiles of GAS representing worldwide diversity of the organism [77].   
 
Discovered in 1970 [78, 79], restriction enzymes utilised in RFLP of GAS 
differentiated emm types based on restriction profiles following digestion of emm 
amplicon [60, 71, 80-82].  Restriction fragment length polymorphism has been 
recommended to developing countries due to promising results observed when 
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characterising the M-protein [71, 80, 83].  The effectiveness of RFLP in GAS studies 
will be further discussed in Chapter Three of the thesis. 
 
1.2.4 Significance of emm typing 
Molecular epidemiological studies utilise the emm typing technique to document 
prevalence of the emm types and in some cases estimate the coverage of M-protein 
based vaccines [10, 11, 84].  As will be elaborated in 1.6.1, the prevalent emm types 
in given area has a big impact on the coverage of M-protein based vaccines. 
 
The emm typing technique has been useful in determining the GAS strain responsible 
for outbreak of certain diseases.  For instance, in China, GAS strains responsible for 
scarlet fever among children were differentiated based on the emm types [32]; 
likewise isolates were differentiated from a scarlet f ver outbreak in Taiwan in 2001 
and 2002 [50].  Similarly GAS responsible for pharyngitis and ARF attacks have also 
been characterised using the emm typing [34, 85, 86].  Frequent isolation of certain 
GAS from disease sites triggers suspicion of the involment of some emm types in 
certain diseases manifestations [34].  For instance, a number of emm types have been 
labelled rheumatogenic due to their association with ARF (emm1, emm3, emm5, 
emm6, emm18, emm14, emm19, emm24, emm27 and emm29) [34, 85]. However, the 
rheumatogenic emm types reported in a particular region may not be a true 
representation of global epidemiology. This is due to the fact that developed and 
developing countries do not share similar emm type distribution;  hence the 
“rheumatogenic emm types” may be accounted for by circulating emm types   
Meanwhile, emm2 has been associated with puerperal sepsis, emm6 mostly 
associated with meningitis and emm12 predominantly with GAS arthritis [35].  Two 
studies investigating GAS isolated from scarlet fever patients identified 
predominantly emm1 and emm12 [32, 50] while emm1, emm3, emm6, emm12, 
emm18, emm19 and emm24 have all been associated with pharyngitis [86].   
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Following emm typing, some superantigens have also been connected with certain 
emm types [30, 35, 87].  Some reports suggest the presence of conserved SAg 
profiles in emm1, emm4 emm12, emm28, and emm75, most notably emm1 which has 
been associated with speA, speG, speJ, and smeZ but lack speC, speH and ssa genes 
[30, 35, 87].  With regards to emm28, one study has shown the present of speC, speG 
and speJ, the lack of speA, speH and ssa genes [30] although this was contradicted 
by another study which identified restriction profiles which depicted both presence 
and absence of these genes in emm28 [42].  Interestingly, different studies have 
shown differences among SAg profiles from similar emm types, suggesting 
discrepancies in the present of certain SAg genes [30, 42]. 
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1.3  Clinical manifestations of infection with GAS 
1.3.1 Non-invasive diseases 
1.3.1.1  Scarlet fever 
Scarlet fever, mostly prevalent among children between 4 to 15 years of age [32], is 
associated with exotoxin SPEA [31] but other toxins such as SPEB and SPEC are 
produced by up to 90% of GAS [88].  Early stages of the disease are associated with 
white coated tongue (white strawberry tongue) and red swollen papillae after 2-3 
days followed by “red strawberry tongue” after 4
th
 and 5
th
 day [89], disseminated 
rash to the head, neck and extremities, but sparing the palms and soles [88].  Post 
streptococcal toxin complications such as septic arthritis, rheumatic fever or post 
streptococcal glomerulonephritis may occur [89].  Epidemiological data on this 
disease remains limited in South Africa. 
 
1.3.1.2  Impetigo 
Impetigo results from superficial infection of GAS and S. aureus on skin [90].  
Nonbullous impetigo occurs after the corneal layer of the epidermis is breached, 
granting GAS access to subcorneal keratinocytes  [91].  The disease is common in 
hot, humid summer weather.  Lack of epidemiological studies on impetigo may be 
the result of underestimation of disease in South Africa, as is the case with other 
streptococcal diseases.  However, in Fiji, at least a quarter of school children (5-15 
years of age) have active impetigo [90]. 
 
1.3.2 Invasive diseases 
Severe skin and soft tissue infections 
The common causative organisms in severe skin and soft tissue infections (SSTI) are 
S. aureus and GAS [87].  Common SSTI conditions are ecthyma, erysipelas, 
cellulitis, bursitis, necrotizing type II fasciitis and Fournier’s gangrene.  A breach in 
skin integrity renders the host susceptible to SSTI caused by GAS [88, 89].  
Antimicrobial therapy with penicillin or clindamycin is often effective in treatment 
of these infections [89].  Epidemiological data on SSTI data are scarce in South 
Africa. 
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1.4   Streptococcal pharyngitis 
1.4.1 Clinical Manifestations 
Pharyngitis is defined as inflammation of the throat behind the soft palate (pharynx) 
[92].  Clinical manifestations such as marked odynophagia, exudative 
tonsillopharyngitis, anterior cervical adenitis, fever and leucocytosis are suggestive 
of infection by GAS [93].  Other symptoms include high temperature, headache, 
abdominal pain and greyish-yellow pharyngeal exudate [94].  Exudative pharyngitis 
is not common in children below three years of age [95].  Symptoms such as cough, 
hoarseness, diarrhoea and conjunctivitis are suggestive of viral infection, hence may 
distinguish bacterial from viral pharyngitis [93]. However, accurate differentiation of 
bacterial pharyngitis from viral is very difficult on clinical grounds alone. 
 
Group A streptococcus is the most common bacterial cause of pharyngitis, primarily 
in children between 5 and 15 years of age [96, 97].  Other bacterial and viral 
etiological agents of pharyngitis exist (Table 1-2).  The global burden of new GAS 
pharyngitis cases has been estimated around 686 million cases annually [97].  
Chronic complications arising post streptococcal pharyngitis include ARF and RHD.  
Although post-streptococcal glomerulonephritis can occur post streptococcal 
pharyngitis, it is more commonly associated with impetigo.  Acute rheumatic fever 
and RHD will be elaborated further in this chapter 
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Table 1-2.  Microbial causes of acute pharyngitis  
Pathogen Syndrome / disease 
Bacterial 
Streptococcus pyogenes (GAS) Pharyngitis/tonsillitis, scarlet fever 
Groups C and G Streptococcus Pharyngitis/tonsillitis 
Mixed aerobic / anaerobic infection  Gingivitis (Vincent’s angina) 
Peritonsillitis/peritonsillar abscess (quinsy) 
Neisseria gonorrhoeae Pharyngitis 
Corynebacterium diphtheria Diphtheria 
Corynebacterium ulcerans Pharyngitis, diphtheria 
Arcanobacterium haemolyticum 
(Corynebactirium haemolyticum) 
Pharyngitis, scarletiniform rash 
Yersinia enterocolitica Pharyngitis, enterocolitis 
Treponema pallidum Secondary syphilis 
Francisella tularensis Oropharyngeal tularemia 
  
Viral  
Rhinovirus  Common cold  
Coronavirus  Common cold, SARS 
Adenovirus  Pharyngoconjunctival fever, ARD 
Herpes simplex  Pharyngitis, gingivostomatitis 
Parainfluenza  Common cold, croup 
Coxsackie A  Herpangina, hand-foot-mouth disease 
Epstein-Barr virus  Infectious mononucleosis 
Cytomegalovirus  Infectious mononucleosis 
Human immunodeficiency virus  Primary HIV infection 
Influenza A, B  Influenza 
 
Chlamydial  
Chlamydophila pneumoniae  Pneumonia, bronchitis, pharyngitis 
Chlamydophila psittaci  ARD, pneumonia 
 
Mycoplasmal 
Mycoplasma pneumonia Pneumonia, bronchitis, pharyngitis 
Mycoplasma hominis (type 1) Pharyngitis in volunteers  
ARD, Acute respiratory disease; GAS, Group A streptococci; SARS, severe acute respiratory 
syndrome. Modified from [93, 98]. 
 
1.4.2 Epidemiology of GAS pharyngitis and asymptomatic carriage of GAS in 
South Africa and other African countries 
Streptococcal pharyngitis is estimated to account for 5 to 15% of pharyngitis in 
adults and 20 to 30 % in children [99].  A plethora of epidemiological data on GAS 
pharyngitis comes from developed countries, while there is relatively little data from 
developing countries [100].  A South African study conducted in 1978 included 
children and teenagers between 2 and 19 years of age presenting with sore throat and 
were investigated for GAS.  Positive cultures were seen in 48 (43%) of 112 children 
[100].  Another study conducted in Pretoria during the winter period (June-August) 
of 1979 and summer (October 1979 to January 1980) found beta-haemolytic 
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streptococci in 33.2% of 232 patients [101]. Data on scarlet fever in South Agrca is 
scant. 
 
Asymptomatic carriage of GAS occurs in the throat of 15% to 20% healthy 
individual [102].  The GAS carriage rate observed in 1982 from a remote area of 
Venda (Limpopo province, South Africa) was 1.62% from 247 asymptomatic 
subjects between 5 and 25 years of age [103].  By contrast, a higher carriage was 
seen in 1983 from a study conducted in Johannesburg which also depicted seasonal 
variation in the prevalence of GAS from asymptomatic school children [104].  The 
children were from two racial groups in South Africa (Coloured and Indians) with 
mean age of 8.2 years for the Coloured and 7.9 years for the Indians children. 
Positive throat swab rates were 24.4% from 120 coloured children and 21.3% from 
126 Indian children.  The higher positive throat swabs within the urban setting may 
possibly be due to the overcrowding within Black communities at that time of South 
Africa’s history, compared with the relatively open expanse of rural Venda  
 
A few studies examining the epidemiology of pharyngitis have emerged from the 
African continent.  A prevalence of 9.3% was reported in Morocco from 697 patients 
(494 children and 203 adults) [105].  The 697 patients were recruited prospectively 
in surveillance of patients presenting with sore throat in Rabat, Morocco from March 
2006 to February 2007.  A similar study looking at 504 children (2 to 10 years of 
age) in Tunisia presenting with sore throat was conducted in a primary care institute 
from June 2007 to May 2008.  The study observed 166 (32.9%) children who were 
culture positive for GAS [106]. 
 
1.4.3 Treatment and control of pharyngitis 
In South Africa, penicillin (oral Penicillin VK or intramuscular injection of 
benzathine penicillin) is the recommended first-line antibiotic for treatment of 
pharyngitis [107].  Intramuscular injection has shown to reduce the occurrence of 
ARF by 71-91% compared to oral administration [108].  Amoxycillin is 
recommended as an alternative to penicillin.  Other antibiotics utilised for treatment 
of pharyngitis include amoxicillin-clavunate, azithromycin, clarithromycin, 
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cefpodoxime, cefprozil and cefuroxime [93, 107]. Alternatively, Alternatively, 
Cephalexin, Cephadroxil, Clindeamycin and Clarithromycin can be used to treat 
patients who are allergic to penicillin as recommended the Infectious Diseases 
Society of America (IDSA) the Infectious Diseases Society of America (IDSA)[109].  
First generation cephalosporin are recommended for patients who do not have 
immediate hypersensitivity to beta-lactam antibiotics [110].  
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1.5   Acute rheumatic fever and rheumatic heart disease 
1.5.1 Chronic but controllable disease: ARF and RHD 
Acute rheumatic fever can follow GAS infection, and usually occurs following 
pharyngitis. Although the pathogenesis of this disease remains a mystery, molecular 
mimicry of the M-protein to the human cardiac myocin and other tissues is largely 
thought to result in development of this disease [111].  Consequently, this triggers 
the host antibody production against myocardium, cardiac connective tissue, valvular 
tissue and the smooth muscle cells of arteries [112].  Reports of rheumatogenic 
epitopes on S2 region of human cardiac myosin have also emerged [113]. The 
damage to cardiac tissue caused by an attack of ARF leads to RHD. At least 15.6 
million people are affected by RHD worldwide [97], with Sub-Sahara Africa holding 
most cases of ARF/RHD [97].   
 
In summary, following infection with GAS and mounting of immune response, GAS 
antigens are presented to CD4 T cells by antigen presenting cells. B-cells are then 
activated to elicit antibodies against GAS cell wall; however these antibodies also 
recognise host proteins in joints, myocardium, cardiac connective tissue, valvular 
tissue and the smooth muscle cells of arteries.  This leads to stimulation of 
inflammatory cytokines followed by stimulation of complement cascade [12], 
neutrophils and macrophages which results in destruction of the host tissue.  The 
aftermath of ARF, mostly as a result of ARF sequelae, present the most common 
heart and vulvular disease in developing countries, RHD [114].  
 
1.5.2 Epidemiology of ARF and RHD in South Africa and Developed world 
The Heart of Soweto study is the first study to present the incidence of new-onset 
RHD cases in patients above the age of 14 in Africa.  Three hundred and forty four 
new cases of RHD were reported with the incidence of new cases calculated at 23.5 
cases/100 000 per annum [115].  Developed countries, particularly the USA, have 
noticed a decline in number of ARF/RHD cases, and this has been attributed to the 
emergence of antibiotics and better living conditions [116].  As a result, an annual 
mean incidence rate of first attack of ARF in the USA and Western Europe is, 0.5-3 
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cases/100000 per annum [112, 117, 118]. The resurgence of ARF, diagnosed by 
echocardiography in Italy between January 2007 and December 2008 revealed an 
incidence of 23 and 27/100000 new cases in 2007 and 2008, respectively, in patients 
5 to 15 years of age [116].  
 
1.5.3 Treatment and control of ARF and RHD 
In Africa, the Pan African Society of Cardiology in collaboration with the World 
Heart Federation and WHO adopted four strategies aimed at curbing the ARF/RHD 
burden.  These strategies involve awareness, surveillance, advocacy and prevention 
(ASAP) [119].  The pillars proposed for the control of ARF and RHD include 
education, primary prevention through penicillin treatment of suspected streptococcal 
sore throat, secondary prevention through register based penicillin prophylaxis and 
surveillance through notification of ARF [120].  
 
Education remains an essential tool in the fight against RHD.  The Drakensberg 
Declaration on the control of ARF and RHD in Africa recognises awareness as 
means of educating the public and healthcare professionals [119].  Awareness of 
ARF/RHD is emphasised among child caregivers, teachers, and health professionals 
[121].  In a study which investigated eight guardians of children affected with 
ARF/RHD, six guardians admitted ignorance of the disease while seven parents 
lacked knowledge of ARF/RHD prior to the child’s diagnosis [122].  The success of 
raising awareness through education can be witnessed by a study conducted in 
French Caribbean Islands (Martinique and Guadeloupe) which documented a decline 
in ARF/RHD incidences by 78% in Martinique and 74% in Guadeloupe, 
respectively, following 10 years of awareness programme on ARF [123]. 
 
Primary prevention of ARF is the first line prevention of the initial ARF attack. 
Penicillin is the main antibiotic proven to contain the burden of ARF/RHD [124].  
Treatment of patients with known or suspected streptococcal sore throat with 
penicillin forms the primary prevention of ARF, hindering its notorious sequelae, 
RHD [124].  A meta-analysis of clinical trials looking at penicillin prescription 
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observed up to 70% reduction of ARF when penicillin was administered to patients 
with symptoms suggestive of streptococcal sore throat [124].  Intramuscular 
benzathine penicillin or oral phenoxymethyl penicillin are recommended for primary 
prevention of ARF [125].   
 
Secondary prevention of ARF is the administration of antibiotic for prevention of 
recurrent ARF attack to individual with history of ARF.  The antibiotics are 
administered to prevent new GAS infections which may result in new ARF attacks.  
Antibiotic treatment for secondary prevention of recurrence of ARF are similar to 
those prescribed for primary prevention of ARF except for single dose recommended 
for primary prevention whereas dosage is given two to four weekly in secondary 
prevention [125].  Intramuscular penicillin is much more effective in prevention of 
recurrence of ARF compared to oral penicillin [108].  When penicillin is 
administered intramuscularly, recurrence of ARF is decreased by 87-96% [108].  
Frequent injections (2-weekly) reduce the recurrence of ARF by up to 50% 
compared to 4-weekly injections [108].  Patients with history of penicillin allergy can 
be treated with oral erythromycin [125].  The WHO recommendations for antibiotic 
duration for secondary prevention of ARF/RHD are presented in Table 1-3. 
 
Table 1-3.  Recommended duration of secondary prevention of ARF/RHD by 
WHO 
Category of patients Duration of secondary prevention 
Patient without proven carditis For 5 years after last attack, or until 18 years 
of age (whichever is longer) 
Patients with mild carditis (mild 
mitral regurgitation or healed 
carditis 
For 10 years after the last attack or at least 
until 25 years of age (whichever is longer) 
More severe valvular disease Lifelong 
After surgery Lifelong  
Adapted from [125] 
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Notification of ARF/RHD is believed to be an important component in controlling 
the burden of this disease [126].  In the South African context, surveillance of 
ARF/RHD in the form of notification has been proven to have discrepancies 
resulting in under reporting of ARF/RHD cases [127].  Proper notification of initial 
diagnosis of ARF/RHD cases may provide more epidemiological data and enhance 
patient’s enrolment in secondary prevention programmes [127].  Since it has been 
proven that patients enrolled in primary prevention are less likely to develop 
ARF/RHD [124], an efficient surveillance system may assist in monitoring the 
incidences of ARF/RHD [126]. 
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1.6 GAS vaccine 
1.6.1 M-protein vaccine 
The M-protein based vaccine is the most recent GAS vaccine to reach  human 
clinical trials [128-130].  The N-terminus domain or hypervariable region of the M-
protein (10 to 35 amino acid residues) elicits an M-protein type-specific antibody, 
making it a vaccine target. M-protein based vaccines containing whole cell or highly 
purified M-protein developed in the 1930s and 1970s were abandoned due to cases of 
rheumatic fever following vaccination [131-135].  However, the development of the 
M-protein based vaccine was given a boost by advances in molecular biology 
towards the end of the twentieth century.  Using recombinant techniques it was 
possible to prepare a vaccine which excluded the harmful tissue cross-reactive 
epitopes [136], thus minimising the possibility of ARF attacks in vaccine recipients. 
Successful immunogenicity of a recombinant tetravalent vaccine (M25, M5, M6 and 
M19) developed in 1993 [137] led to development of an octavalent vaccine (M24, 
M5, M6, M9, M1, M3, M18 and M2) in 1996 [138].  However, subsequent to the 
development of both the tetravalent and octavalent GAS vaccine, the carboxy-
terminus components of the vaccine were found to have no immunogenicity or 
elicited low levels of antibodies that were not opsonic.  Thus, in 1999 a vaccine 
containing six M-proteins (M24, M5, M6, M19, M1, and M3) was designed to 
optimize the immunogenicity [139].  Broader multivalent GAS vaccines containing 
26 and 30 M-proteins were introduced in 2002 and 2011, respectively (Table 1-4) 
[140, 141].  The GAS vaccine containing 30 M-proteins is anticipated to have 
potential coverage that may extend beyond the M-proteins incorporated in the 
vaccine [140].  The global coverage of the experimental 26-valent vaccine has been 
estimated at 69.7% [11] while in North America, the figure is thought to be 85% 
[142].  At the time of writing this thesis, no published data on the efficacy and 
coverage of the 30-valent GAS vaccine were available. 
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Table 1-4.  Progress in development of M-protein vaccine 
Year Vaccine M-proteins included Ref 
1983 M5 vaccine M5 [136] 
1993 tetravalent M25, M5, M6 and M19 [137] 
1996 octavalent M24, M5, M6, M9, M1, M3, M18 and M2 [138] 
1999  M24, M5, M6, M19, M1, and M3 [139] 
2002 26-valent M24, M5, M6, M29, M14, M1, M12, M28, M3, M1.2, M18, M2, 
M43, M94, M22, M11, M59, M33, M89, M101, M77, M114, M75, 
M76, M92, spa 
[141] 
2011 30-valent M1, M3.1, M6.4, M2, M18, M28, 12, spa, M4, M5.14, M11, M75, 
M19, M29.2, M14.3, M24, M77, M22, M73, M89, M58, M44, M78, 
M118, M83.1, M82, M81, M87, M49, M92, M114 
[140] 
spa, streptococcal protective antigen 
 
The 26-valent vaccine remains the only GAS vaccine that has entered clinical trials 
after the year 2000 yet researchers are still concerned over geographical differences 
in the distribution of M-protein.  With over 150 known M-proteins and only 30 of 
these protein included in the recent 30-valent vaccine [140], geographical 
distribution of emm types remains a concern although the developers of the 30-valent 
vccine have notice vaccine coverage that extends beyond the emm types included in 
the 30-valent vaccine [11].  Since global distribution of emm types has shown 
geographical differences among prevalent emm types in developed countries and 
developing countries (Table 1-1) [11] and only emm types of epidemiological 
importance in developed countries are included in the vaccine [140], the formulation 
of the 26-valent and the 30-valent vaccine has proved its potential effectiveness in 
developed countries but less effective in developing countries [11]. 
 
1.6.2 Conserved region of the M-protein: Answer to M-protein vaccine? 
The C-repeats of M-protein are highly conserved across GAS strains [143], a 
property that brings hope of developing a GAS vaccine that does not confer type 
specificity, hence ideal for coverage of the multiple GAS strains [144].  Human 
serum albumin, CD46 and factor H bind to this proximal region of the M-protein 
[143].  Two peptide sequences on the C-repeats, J8 and J14 [145], when intranasally 
and subcutaneously delivered in mice models elicit immune response [146].  
Following intraperitoneally challenging mice with GAS, immunized mice (10 days 
following immunization) showed a higher anti-J14 antibody titre, protecting 66-83%, 
contrasting with non-immunised mice with survival of between 0 to 16.6% [145].  
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Similarly, another study has shown 84% survival of mice immunised with J14 
compare to 20% for non-immunized [147].  The C-repeat region of the M-protein 
will be discussed further in Chapter Four. 
 
1.6.3 Non–M-protein vaccine 
Mounting concerns over the M-protein’s contribution to possible cross-reactivity 
with human tissues [131-135] and a low coverage reported in some developing 
countries [11] have contributed to the quest for alternative vaccine candidates.  To 
date, a number of potential non-M-protein vaccine candidates have been proposed.  
These include streptococcal pili, streptococcal C5a peptidase and streptococcal 
hemoprotein receptor (shr). 
 
Group A streptococcal pili are involved in bacterial-host interaction.  This 
relationship is enhanced by the ability of pili to adhere onto host epithelial cells and 
form biofilm [20, 148].  The extracellular exposure of pili confers vaccine developer 
an opportunity to explore the potential use of this component of GAS as a vaccine 
target [149-152].  The pili based vaccine has been anticipated to confer protection 
against more than 90% of GAS strains [151].  
 
C5a peptidase is a virulence factor of GAS which evades the complement system by 
inactivating serum chemotactic activity [153].  Group A streptococci have similar 
C5a peptidase hence this can serve as a vaccine target across GAS strains [154, 155].  
When immunized with C5a peptidase, immunized mice cleared GAS from the 
nasopharynx and prevented nasopharyngreal colonisation compared to unimmunized 
mice [155].  Vaccination with streptococcal C5a peptidase derived from GAS 
induced sufficient immune response to clear streptococci from nasopharynx. Hence 
the C5a vaccine is anticipated to confer protection that will assist in clearance of skin 
infections [156].  Although there is promising progress in the development of C5a 
peptidase vaccine, human trials are yet to be conducted on this vaccine. 
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Streptococcus pyogenes requires hemoprotein receptor for iron acquisition although 
other mechanisms exist [157].  This haemoglobin binding protein is conserved 
among S. pyogenes, imbedded in the membrane and capable of inducing host 
immune response [157, 158].  Mice models challenged with purified streptococcal 
hemoprotein receptor (shr) expressed on Lactococcus lactis elicited shr-specific IgG 
and IgA after intraperitoneal and intranasal immunization, respectively [159].  
Encouraging results were also observed from passive immunity with rabbit shr 
antiserum rendering this vaccine target essential in production of rabbit antiserum 
that may be used in the therapy of invasive diseases such as streptococcal toxic shock 
syndrome [159].  A vaccine targeting shr is also yet to proceed to clinical trials. 
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1.7   Conclusion 
South Africa is among the developing countries which the prevalent of both ARF and 
RHD is still highly under reported [2, 5].  By the year 2010, 23.5 new cases of 
RHD/100000 per annum had been estimated [115], among the highest in the world 
yet the etiological agent, S. pyogenes (GAS) has not drawn attention from South 
African researchers.  South Africa, together with other developing countries, is 
trailing in the efforts of containing the burden of ARF and RHD [127, 160].  This can 
be attributed to, in part, a lack of streptococcal data which, when intensively 
documented, can improved the understanding of GAS diseases epidemiology and 
change the approach towards this devastating disease.  The extent of ARF and RHD 
in South Africa calls for a full investigation of the molecular epidemiology of GAS 
to best understand the circulating M-protein types, the most prominent virulence 
factor as well as a vaccine target.  Early studies date back to the 1970s and 1980s 
[100, 101, 103, 104], and from the 1990s to the  present, very few clinical or 
laboratory based studies have surfaced from South Africa, a handful being conducted 
by researchers in the aspects of ARF and RHD [119-122, 124, 125, 161].  
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SCOPE AND OBJECTIVES OF THE THESIS 
 
Aim 
• The primary aim of this study was to describe the molecular epidemiology of 
GAS isolates causing pharyngitis in children from Cape Town  
• To estimate the coverage of the 26-valent GAS vaccine in the context of the 
molecular epidemiology of GAS from children in Cape Town 
 
Objectives 
• To perform emm typing of GAS isolates causing pharyngitis using PCR and 
DNA sequencing 
• To perform RFLP analysis of the GAS isolates causing pharyngitis and to 
determine whether this approach is a useful alternative to sequence based 
analysis in South Africa 
• To characterise the C-repeats of the M-protein using DNA sequence analysis 
• To determine the SAg gene profile of pharyngeal strains of GAS 
• To investigate the association between the presence of certain SAg and emm 
types 
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Chapter Two: emm typing 
 
Characterisation of the emm gene using sequencing  
 
2.1       Introduction 
Although GAS has a number of potential vaccine targets, M-protein has become the 
most favourable and highly researched [46, 47, 129, 162].  M-protein is encoded by 
the emm gene [8] and consists of four structural repeat blocks that have been 
intensively explored in epidemiological studies of GAS [8].  The four repeat blocks, 
namely A-D (Figure 2-1), comprise amino acid sequences of different sizes [8].  
Block A is hypervariable, block B is semi-variable, while block C is located 
proximal to the cell membrane and highly conserved among the GAS strains [102]. 
 
 
   Figure 2-1.  Schematic representation of the four repeats of M-protein 
based on literature [163].  
 
The development of more broadly protective vaccines has resulted from an increased 
understanding of the epidemiology of GAS [142, 164].  The molecular technique of 
emm sequence typing of the N-terminal region of M-protein, was developed in 1996 
and has subsequently become the method of choice for studying the molecular 
epidemiology of GAS [9, 10].  Briefly, the technique involves the amplification of a 
Key:
A Repeat
B Repeat
C Repeat
D Repeat
Cell
D BC A
M protein
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large portion of the emm gene in a PCR assay and DNA sequencing of the N-
terminal region is used to determine the emm type [10, 165]. 
 
A comprehensive review of articles and reports on the distribution of emm types 
revealed a plethora of data from developed countries compared with those from less 
developed countries [84].  Currently, Ethiopia and Tunisia are the only African 
countries which have documented the emm types circulating in their population [46, 
48].  The Ethiopian study comprised 82 GAS isolates from throats of asymptomatic 
school children (6-14 years of age) while the Tunisian study included 103 isolates 
[46, 48].  In Ethiopia, 43 different emm types were identified in 82 GAS isolates with 
emm3.19 being the most prevalent; whereas in Tunisia 38 emm types were identified 
in 103 GAS isolates with emm118 the most prevalent in the GAS studied.  These 
emm types were not common in studies on GAS reported from North America (USA 
and Canada) and Europe [142, 166].  The surveillance study from North America 
identified 56 emm types in 7040 GAS isolates from the USA among which emm1 
and emm12 were the most prevalent [142].  In the same study involving 1434 GAS 
isolates from Canada, similar results were obtained [142].  As outlined earlier (1.2.2) 
the distribution of emm types in Europe is similar to those seen in North America.  In 
Germany, among 216 isolates investigated, emm1 and emm12 were the most 
prevalent at 18.5% and 15.7% respectively. [58]. 
 
Epidemiological studies suggest a geographical difference in the distribution of GAS 
[11].  Because data from the developed world have been used to inform the selection 
of emm types in the 26-valent vaccine, the potential coverage of this vaccine is 
greater in these countries than in the developing countries [46, 64, 84, 166].  An 
Ethiopian study demonstrated that 46% of the 43 emm types were not included in the 
26-valent GAS vaccine [46].  The low coverage in developing countries is primarily 
due to the lack of epidemiological studies that could be used to informing the 
selection of relevant emm types included in the vaccine [84].   
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Currently, no epidemiological data exists on the molecular epidemiology of GAS in 
South Africa; thus, the protective coverage of the 26-valent vaccine is unknown.  
This study aims at presenting the first examination of emm types in Cape Town, 
South Africa. 
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2.2       Experimental protocol 
The emm typing technique involves a number of steps which are detailed below 
(Figure 2-2).  As an overview, the procedure begins with the culture and 
identification of GAS from throat swab samples (A), after which DNA is extracted 
(B) and subjected to PCR amplification of the emm gene (C).  The PCR products are 
separated and visualized using agarose gel electrophoresis (D), purified (E) and 
sequenced (F).  The DNA sequences generated are submitted to the CDC for 
comparison with sequences in existing databases (G) thereafter the submitted 
sequence is assigned an emm type; e.g., emm2 and when necessary a subtype, 
emm2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2.  Sequence of steps in emm typing.  A culture and 
identification of GAS.  B genomic DNA extraction. C PCR amplification 
of the emm gene.  D Agarose gel electrophoresis.  E Purification of PCR 
amplicons.  F sequencing of emm PCR products.  G sequence submission 
to CDC database for assignation of emm types. 
 
 
 
 
 
A B C D 
E F G 
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2.2.1       Selection of study population 
Participants for this study were from Bonteheuwel and Langa, two periurban 
communites located approximately 10 kilometers from the central business distract 
of Cape Town [See Map].  The area is characteristed by lower socioeconmic 
conditions with high unemployment and a significant proportion of the residents of 
Black or mixed ancestery, living in informal housing.  Pharyngeal isolates were 
collected from May 2008 until April 2012 from two groups of children:  the first 
group, consisted of children between the ages of 3 and 15 years presenting with a 
sore throat to the Vanguard Community Health Centre. A research nurse obtained 
informed consent from parents or legal guardians of the children prior to their 
enrolment in the study, and then obtained pharyngeal swabs from the children.  
Individuals who received antibiotics within 30 days of enrolment were excluded.  
Where parents were unavailable or unwilling to allow participation in the study, the 
children were excluded with no predujice.  The second group, consisting of 
asymptomatic school children across all school grades, had throat swabs taken after 
informed consent.  Children older than 8 years had to provide assent in addition to 
the parents providing consent.  Throat swabs were submitted to the National Health 
Laboratory Services, Microbiology Laboratory at Groote Schuur Hospital for culture 
and isolation of GAS.  
 
 
Map:  The Vanguard Community Demonstration Site 
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2.2.2       Culture and identification of β-haemolytic streptococci  
Upon receipt at the Microbiology Laboratory, samples were inoculated on 2% blood 
(horse) agar and incubated in the presence of 5% CO2 for 48 hours at 37°C (NuaAire 
Inc, USA).  Culture on blood agar (horse) represents the gold standard for isolation 
of S. pyogenes [167].  Streptococcus pyogenes is requires supplementation of whole 
blood for observation of beta-haemlysis hence assist identification [167].  The 
colonies were further identified using a commercial streptococcal serogrouping kit 
by the Microbiology Laboratory.  Isolates identified as belonging to Lancefield 
Group A, C or G were stored in storage media containing beads a -70°C freezer 
(New Brunswick Scientific, England). Only isolates conformed as belonging to 
Lancefield Group A were investigated further. 
 
2.2.3       Genomic DNA extraction 
Isolates were subcultured from frozen stocks onto blood agar and incubated in 
presence of 5% CO2 for 24 hours. Single colonies were suspended in 1 ml of 
autoclaved water in Eppendorf tubes (Eppendorf, Germany).  After emulsifying the 
colonies, the bacteria were pelleted using a microfuge for 1 minute at 16500 x g 
(Eppendorf, Germany).  The supernatant was discarded and genomic DNA was 
extracted from the bacterial pellet using an InstaGene matrix DNA extraction kit 
(Bio-Rad, France) as recommended by the manufacturer.  Using a 1000 µl pipette 
tip, as instructed, InstaGene matrix was added to the pellet and incubated for 30 
minutes at 56°C (Kendro, German).  After incubation, the tubes were vortexed at 
level 8 on a Vortex-2 Genie (Scientific Industries, USA) for 10 seconds and placed 
on a heating block (Techne LTD, USA) at 100°C for 8 minutes.  The Eppendorf 
tubes were then vortexed again at level 8 for 10 seconds followed by centrifugation 
in a microfuge at 16500 x g for 3 minutes.  The supernatant, containing the extracted 
DNA, was used as a template for PCR amplification. 
  
2.2.4       Polymerase chain reaction 
The emm gene was selectively amplified using PCR according to the CDC protocol 
[10, 168].  This molecular method selectively amplifies a target gene or a portion of a 
gene.  The amplification is achieved by the use of sequence-specific 
oligonucleotides, often referred to as primers.  Primers work in pairs by binding on 
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either strand of double-stranded DNA. The primers used in emm typing anneal to a 
conserved sequence internal to the emm gene [168].  The primers (Table 2-1) used in 
this assay were synthesized at the Department of Molecular and Cell Biology, 
University of Cape Town, South Africa.  Polymerase chain reaction amplification of 
DNA is achieved by the work of an enzyme called DNA polymerase I (Taq 
Polymerase) [169] isolated from the bacterium Thermus aquaticus [169].  Taq 
Polymerase has the ability to withstand high temperatures during PCR cycles.   
 
Table 2-1.  Primers used for emm typing 
Target gene Primer  Primer sequence 
emm gene Primer 1 (forward) TAT T(C/G) GCT TAG AAA ATT AA  
 Primer 2 (reverse) GCA AGT TCT TCA GCT TGT TT 
 Emmseq2 TAT TCG CTT AGA AAA TTA AAA ACA GG 
   
 
 
To achieve a successful amplification of the emm gene, a combination of reagents 
were used at specific concentrations recommended by the CDC [168].  PCR reagents 
comprised 1X buffer, 1.5 mM MgCl2, 0.2 mM dNTP, 70 picomol/µl of the forward 
and reverse primers and 1.5U of SuperTherm Taq (JMR, Holdings, London UK) then 
brought to a final volume of 50 µl with DNAse-free water.  
 
Cycling conditions for amplification of the emm gene involves the three basic 
principle amplification steps during PCR, namely; denaturation, annealing and 
elongation.  Cycling conditions for emm typing, as recommended by the CDC [168], 
begins with initial denaturation at 94ºC for a minute followed by 30 cycles of 
denaturation at 94ºC for 15 seconds, annealing at 46.5ºC for 30 seconds and 
extension at 72ºC for 75 seconds.  Additional 20 cycles follow with denaturation at 
94ºC, annealing at 46.5ºC for 30 seconds, extension at 72ºC for 75 seconds with a 10 
second increment for each of the subsequent 19 cycles.  Final extension was carried 
out at 72ºC for 10 minutes. 
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2.2.5       Agarose gel electrophoresis 
Agarose gel electrophoresis is a technique used to separate DNA fragments based on 
their sizes [170] when subjected to an electrical current.  DNA has a negative charge 
due to the phosphate groups on its sugar-phosphate backbone and thus migrates to 
the positive end of the agarose gel when an electric current is passed through the gel.  
The percentage of agarose within a gel determines the pore size; hence different 
percentages of gels are prepared based on the size of DNA fragments to be separated.  
Larger DNA fragments migrate slower through an agarose gel than smaller 
fragments [170].  
 
Agarose gel electrophoresis was used to separate the DNA fragments following PCR. 
As the expected sizes of emm amplicons range from 750 bp to 1400 bp, a 2% agarose 
gel was used to separate the PCR products.  Agarose (SeaKem
® 
LE Agarose, Lanza, 
USA) was dissolved in 1X TAE buffer (Appendix A) and ethidium bromide (10 
ng/µl), which intercalates between base pairs of DNA and fluoresces under 
ultraviolet light.  Eight microliters of the PCR product was loaded into each well, 
with 2 µl of loading dye.  The fragments were separated by passing an electric 
current through the agarose for 3 hour of 60V to allow the negatively charged DNA 
fragments to migrate towards the positive electrode.  The rate of migration is 
inversely proportional to the size of the fragments. A molecular marker 
(HyperLadder IV, Bioline, UK) was included to enable estimation of emm amplicon 
sizes.  
 
2.2.6       DNA purification 
The DNA sequencing assay is very sensitive and requires a purification step to 
minimise inhibition by PCR reagents within the sample.  The MinElute PCR 
purification kit (Qiagen, Valencia, CA, USA) incorporates spin-column technology 
using silica-gel membranes with selective binding properties to purify DNA directly 
from PCR products. 
 
Five volumes of PB buffer was added to one volume of PCR product and mixed as 
per manufacturer’s instructions.  To achieve a pH of 5.0 as recommended, 10 µl of 3 
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M sodium acetate was added and mixed.  The mixture was then added to 2 ml 
MinElute columns and centrifuged in a microfuge (Eppendorf, German) for 1 minute 
at 17900 x g.  The flow through products were discarded and 750 µl of Buffer PE 
was added to the column which was again centrifuged for a minute at 17900 x g. 
Again, the flow through product was discarded and the column was centrifuged for a 
minute at 17900 x g.  MinElute columns were then transferred to sterile 1.5 ml 
Eppendorf tube and the DNA was eluted following the addition of 10 µl EB buffer to 
the centre of the column membranes and centrifuged for a minute at 17900 x g.  
Purified DNA products were stored at 4ºC. 
 
2.2.7       Sequencing and assigning emm types 
Sequencing of purified DNA was done using the ABI Prism® BigDye
TM
 Terminator 
Cycle Sequencing kit (Applied Biosystems, USA) at Stellenbosch University, South 
Africa.  The DNA concentration was adjusted to 10 ng/µl for amplicon less than 
1000-bp and 20 ng/µl for amplicons more than 1000-bp as recommended by the 
sequencing facility at the Stellenbosch University, South Africa.  Primer emmseq2 
(Table 2-1), recommended by the CDC, was prepared to 1.1 ng/µl and used for 
sequencing reaction [168].  Sequences generated were analysed using BioEdit v7.0.9 
(Ibis Biosciences, USA).  The sequences were submitted electronically to the S. 
pyogenes emm sequence database centre at the CDC which assigned all the emm 
types and subtypes [45].  
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2.3       Results  
2.3.1       emm types from GAS 
A total of 143 GAS isolates obtained from children aged between 5 and 12 years 
were included for emm typing. Symptomatic children contributed 118 isolates while 
25 came from asymptomatic children.  Initial confirmation of successful 
amplification was observed on a 2% agarose gel.  Following PCR and agarose gel 
electrophoresis, amplicons ranging in size from 720 bp to 1150 bp were generated 
from the isolates, as illustrated in Figure 2-3. 
 
                                                                                           
Figure 2-3. PCR amplicons of emm gene after electrophoresis on a 
2% agarose gel. Lanes 1 and 13 are molecular markers. Lanes 2-11 are 
different clinical isolates of GAS. Lane 12 is a negative control of 
distilled water. 
 
Sequences were obtained from all of the 143 isolates.  Where necessary, electronic 
sequences were edited using information on the BioEdit chromatogram. Edited 
sequences were assigned a particular sequence type by the CDC BLAST-emm [45].  
An emm type was assigned to each of the 143 isolates (Table 2-2). As shown in 
Table 2-2 and in the bar graph (Figure 2-4) a total of 35 different emm types and 
subtypes were identified with emm48.1 being the dominant type.  The eight most 
- 10000 bp 
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prevalent emm types in descending order, accounted for 58% of the isolates, emm48, 
emm12, emm4, emm89, emm94, emm75, emm1 and emm22 (Table 2-2). Of the emm 
types identified in this study, 14 are included in the 26-valent GAS vaccine while 16 
feature in the novel 30-valent vaccine (Table 2-2) [140, 141]. 
 
 
 
Figure 2-4. The diversity and distribution of emm types. The red bar indicates emm 
types not included in the 26-valent vaccine. 
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Table 2-2.  The emm sequences (in descending order) recovered from symptomatic 
and asymptomatic children in Cape Town, South Africa 
emm 
subtype/subtypes 
n (symptomatic/asymptomatic) % Included in the  
26-valent 
vaccine* 
Included in the  
30-valent vaccine* 
emm48.1 17 (16/1) 12 No No 
emm12 13 (9/4) 9 Yes Yes 
emm4 11 (9/2) 8 No Yes 
emm89 9 (7/2) 6 Yes Yes 
emm94 9 (9/0) 6 Yes No 
emm75 9 (6/3) 6 Yes Yes 
emm1.0 8 (6/2) 5.6 Yes Yes 
emm22.0 7 (7/0) 5 Yes Yes 
emm2.0 6 (4/2) 4 Yes Yes 
emm9.2 6 (5/1) 4 No No 
emm87 5 (3/2) 3 No Yes 
emm80.0 4 (4/0) 2.7 No No 
emm116.1 3 (2/1) 2 No No 
emm82.0 3 (3/0) 2 No Yes 
emm3 3 (3/0) 2 Yes Yes 
emm6.4 3 (3/0) 2 Yes Yes 
emm8.0 3 (3/0) 2 No No 
emm44.0 2 (2/0) 1.3 No Yes 
emm53.0 2 (2/0) 1.3 No No 
emm58.2 2 (1/1) 1.3 No Yes 
emm73 2 (1/1) 1.3 No Yes 
emm77 2 (2/0) 1.3 Yes Yes 
emm92 2 (2/0) 1.3 Yes Yes 
emm28.0 1 (1/0) 0.7 Yes Yes 
emm33 1 (1/0) 0.7 Yes No 
emm49.0 1 (0/1) 0.7 No Yes 
emm85 1 (1/0) 0.7 No No 
emm118.1 1 (0/1) 0.7 No Yes 
emm15 1 (1/0) 0.7 No No 
emm43 1 (1/0) 0.7 Yes No 
emm64 1 (1/0) 0.7 No No 
emm82.1 1 (1/0) 0.7 No No 
emm9 1 (1/0) 0.7 No No 
emm6.63 1 (0/1) 0.7 No No 
st2002.2 1 (1/0) 0.7 No No 
Total 143 100% 14/35 (51.7%) 16/35 (62.9%) 
* Refer to Table 1-4 for vaccine contents. 
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2.4       Discussion  
This study reports on the emm types obtained from 143 pharyngeal isolates.  A total 
of 35 emm types were identified with eight emm types; emm48, emm12, emm4, 
emm89, emm22, emm94, emm1 and emm75, comprising 58% of the isolates.  Of the 
emm types labelled as rheumatogenic; due to their association with ARF, only emm1, 
emm3, and emm6 were identified in the isolates from Cape Town.  Each of emm3 and 
emm6 were isolated from two patients while emm1 was the seventh most prevalent 
emm type (Table 2-2).  Interestingly, previously reported rheumatogenic emm types, 
emm5, emm18, emm14, emm19, emm24, emm27 and emm29, not identified in this 
study are thought to be disappearing [85]. 
 
Previous studies from Africa have reported greater emm diversity than was observed 
in GAS from Cape Town.  One study from Ethiopia identified 43 emm types in 82 
GAS isolates [46] while 38 emm types were obtained from 103 GAS isolates from 
Tunisia [48] compared to 35 emm types from 143 Cape Town GAS.  While the emm 
diversity in Cape Town may be lower than observed in the other two African 
countries, it is higher than the corresponding diversity observed in GAS from North 
America, Canada and Europe.  Only 56 and 33 emm types were identified in 7040 
US and 1434 Canadian GAS, respectively [67].  Studies from Europe show a similar 
diversity to that observed in North America.  An Italian study that included 207 GAS 
strains obtained 32 emm types [166], while 25 emm types were reported from 140 
Austrian GAS isolates [57].  Similarly, 19 emm types were identified from 101 and 
147 GAS isolates from both Norway and Romania respectively [61, 62]. 
 
Among the isolates in this study, the emm types were not evenly distributed as some 
were common than others. The distribution of emm types was not even amongst 
Cape Town isolates. Eight emm types accounted for 58% of the isolates with emm48 
being the dominant type, comprising 12% of the GAS (Table 2-2).  In Tunisia, eight 
emm types accounted for 66% of the isolates with emm118 being dominant (9.7%).  
This emm type was not identified in the Cape Town GAS; conversely, the dominant 
local type (emm48) was identified in only one isolate from Tunisia [48].  The 
distribution of emm types in Ethiopia was broader than observed in both Tunisia and 
Cape Town.  In Ethiopia, the eight most common emm types accounted for 38% of 
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the GAS with the dominant emm3.19 contributing 15% of the isolates.  This emm 
type was not identified in isolates from both Cape Town and Tunisia (Table 2-2).  
A comparison of the five most frequently identified emm types, emm48, emm12, 
emm4, emm89, emm94, in Cape Town with the corresponding global information is 
presented in Table 2-3.  
 
Table 2-3.  Five prevalent emm types from Cape Town and other parts of the 
globe 
Country Sampled 
isolates 
Number of 
emm types 
Prevalent emm types (in descending order of 
prevalence)  
Reference 
Cape Town 143 35 48, 12, 4, 89, 94 This study 
UAE 38 25 st3211, 89, st0721, 78.3, st4695 [56] 
Lebanon 103 33 1, 22, 28, 88, 4 [55] 
Germany 216 17 1, 12, 3, 28,4 [58] 
Sweden 1 519 æ 89, 81, 28, , 12, 77 [171] 
USA 7 040 56 1, 12, 28, 4, 3 [67] 
Canada 1 434 33 12, 1, 28, 4, 3,  [67] 
Brazil 128 48 53, 22, 49, 58, 83 [69] 
UAE-United Arab Emirates  
USA-United States of America 
æ – not indicated  
 
While there is some overlap between emm types identified in Cape Town and in 
other parts of the world as shown in Table 2.3, there are marked differences between 
the prevalence of individual types across the countries.  For instance, emm48 was the 
most prevalent in Cape Town GAS but was not identified in the USA, Canada and 
Germany [58, 67].  On the other hand, emm1 which was prevalent in the USA, 
Canada and Germany [58, 67], comprised only 6% of the Cape Town GAS.  Data 
collected through the Strep-EURO program revealed ten prevalent emm types in 
Europe; emm1, emm28, emm3, emm89, emm87, emm12, emm4, emm83, emm81 and 
emm5 [64].  Seven of these isolates; emm1, emm28, emm3, emm89, emm87, emm12 
and emm4, comprising 38.4% of the GAS, were identified in Cape Town (Table 2.2).   
 
In a study from Lebanon involving 103 GAS, emm22 and emm4 accounted for 8.73% 
and 6.79% of the isolates, respectively [55].  These two emm types featured in Cape 
Town, accounting for a combined 13% of the GAS (Table 2-2).  A study by Alfaresi 
in the UAE revealed differences between emm types from that country and those 
identified in Cape Town, as well as the USA and Europe (Table 2-3).  Among the 
five most prevalent emm types, only emm89 identified by Alfaresi was observed in 
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Cape Town (Table 2-3).  A study of 34 GAS from India identified 22 emm types of 
which only one of the Cape Town isolates (emm49, 0.7%) was identified [53]. 
 
The efficacy of the experimental 26-valent GAS vaccine was considered in the 
context of the Cape Town isolates and other regions.  Of the emm types identified in 
Cape Town, 14 of the 35 emm types are contained in the vaccine, accounting for an 
estimated coverage of 51.7% of the study population.  In Ethiopia, 46% of the emm 
types were represented in the 26-valent vaccine [46].  On the other hand, coverage of 
the 26-valent vaccine has been estimated at 85% in the USA [142] and 69% in 
Europe [64].  An extensive review of emm type studies and reports from different 
parts of the world [11], estimated vaccine coverage of 43.7% from pharyngeal 
isolates in Africa and an overall coverage of 39% from all GAS diseases.  Apart from 
China which has reported an overwhelming 93.5% vaccine coverage of their 
pharyngeal isolates [49], coverage of the 26-valent vaccine is lower in developing 
countries than in developed countries [46, 49, 56].  
 
Recent development of a 30-valent vaccine is expected to have broader efficacy due 
to opsonisation with M-proteins which were not included in the previous 26-valent 
vaccine [140].  Eleven emm types, (emm4, emm29, emm73, emm58, emm44, emm78, 
emm118, emm82, emm83, emm87 and emm49) not included in the former 26-valent 
vaccine are featured in the new 30-valent vaccine [140].  Five of these additions 
(emm4, emm44, emm82, emm87 and emm49) were identified in Cape Town (Table 2-
2).  The inclusion of the emm types in the novel 30-valent vaccine was based on 
epidemiological data from North America, CDC and a StrepEuro study.  Of the types 
present in the initial 26-valent vaccine but excluded from the novel 30-valent 
vaccine, emm33 and emm43 were identified in this study.  Although the included 
types do not alter the vaccine coverage in Cape Town significantly, 51.7% in the 26-
valent vaccine compared to an estimated 63% in the 30-valent vaccine, the novel 
vaccine evokes cross-opsonic bactericidal antibodies against non-vaccine serotypes, 
[172] [140]. However, during writing of this thesis, the cross-opsonic bactericidal 
antibodies observed was still under investigation [172]  The cross-opsonic antibodies 
evoked by the 30-valent vaccine against GAS will be welcomed in South Africa and 
the developing countries.  
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This data on the prevalent emm types from Cape Town provide a snapshot of the 
distribution of emm types circulating among Cape Town children. The data enhances 
our understanding of circulating emm types essential for consideration of a vaccine 
that will include emm types of epidemiological importance to the South African 
population.  
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Chapter Three: Restriction digestion  
 
Characterisation of the emm gene using restriction fragment length 
polymorphism 
 
3.1   Introduction 
Since its introduction in 1996, emm typing has been the method of choice to study 
the molecular epidemiology of GAS [9, 10].  However, this sequence based 
technique is impractical in some developing countries where sequencing facilities are 
scarce or costly.  An alternative approach, restriction fragment length polymorphism 
(RFLP), has been used in the characterisation of the peptidyltranferase region of the 
23S rRNA from Helicobacter pylori, the flagellin A gene from Campylobacter jejuni, 
the omp1 gene from Chlamydia trachomatis and the emm gene from GAS [60, 71, 
80, 81, 173-177] 
 
PCR-RFLP is a technique in which nucleotide polymorphisms in a DNA sequence 
are used as markers to identif  differences between specific genes from different 
organisms.  Restriction endonucleases used in PCR-RFLP are enzymes which cleave 
DNA at a known sequence, usually 4-8 nucleotides long.  Thus nucleotide 
polymorphisms at restriction sites will result in an enzyme being unable to cleave the 
DNA. Variations in restriction profiles are then used to detect the polymorphisms 
and identification is based on an individual profile in relation to those of others.  
Single enzyme digestion using the enzymes MboI, DdeI or SacI, and double 
digestion using HaeIII and HincII, have been recommended by the CDC for 
characterisation of emm types.   
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Although RFLP has proven useful in the characterisation of the M-protein, on its 
own, RFLP is not always able to elucidate the M-protein type and is frequently 
coupled with emm typing [66, 80].  However, better and well documented banding 
patterns associated with individual emm types could facilitate identification of emm 
types using RFLP.  This chapter describes the use of RFLP to characterise local M-
protein as an alternative to emm typing.  
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3.2       Experimental protocol 
3.2.1       Sample selection  
A total of 63 of the 143 isolates described in Chapter Two were included in this part 
of the study.  These 63 isolates were chosen to provide at least two to three 
representatives of each of the 23 commonest emm-types (based on the results in 
Chapter 2). For reasons of practicality, at maximum of three isolates of a given emm-
type were chosen. By analysing at least two representative isolates of each of these 
emm-types, the reproducibility of the RFLP assay could be evaluated.  RFLP 
analysis of, emm-types that only occurred in one isolate was not performed. 
 
3.2.2      Prediction of restriction product sizes 
Using the New England Biolabs (NEBcutter V2.0) website [178] and DNA 
sequencing data from the GenBank and some DNA sequences provide by Pierre 
Smeesters from Université Libre de Bruxelles Belgium, restriction enzyme maps 
were generated for all the twenty three emm-types included in this section of the 
study. The primer binding sites were localised using BioEdit v7.0.9 (Ibis 
Biosciences, USA) and excess nucleotides from either flanking region of the five 
prime and three prime were trimmed to mimic the PCR product sizes that would be 
expected on agarose gel electrophoresis. As recommended by the CDC, DdeI, MboI 
and SacI were chosen for ingle digests and HaeIII and HincII for double digests. 
 
3.2.3       Restriction enzyme digestion 
Between 100-200ng of the each of the emm amplicons (2.2.3-2.2.6) estimated using 
PCR amplicon intensity (Appendix B) following agarose gel electrophoresis were 
digested with 5U of DdeI, MboI or SacI, or HincII and HaeIII in the recommended 
buffers (NEB, USA) and  1X bovine serum albumin (BSA) (NEB, USA).  Reactions 
were made up to a final volume of 20 µl in molecular grade water (Promega, USA) 
and incubated in a waterbath at 37ºC for 60 minutes. 
 
Restriction products were separated on 3% agarose gel (SeaKem
® 
LE Agarose, 
Lanza, USA) containing EtBr (0.5µg/ml) for 6 hours at 60V (2.2.5) and 
photographed.  
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3.3       Results 
3.3.1       Prediction of restriction maps by the NEBcutter 
The NEBcutter V2.0 was able to excise DNA sequences where restriction sites were 
available. The program also provided possible sizes of restriction products as it 
would be expected on agarose gel electrophoresis (Figure 3-1). The nNEBcutter 
results were in conjuction with PCR products observed in agarose gel 
electrophoresis. 
 
 
Figure 3-1. NEBcutter digest. Graphical simulation of anticipated 
restriction map of emm12 sequence obtained following HaeIII and HincII 
digest using NEBcutter V2.0. 
 
3.3.2       Restriction digestion using DdeI  
Restriction digestion with DdeI produced three to five restriction bands ranging 
between 50 and 500-bp (Table 3-1).  At least two and where possible three isolates of 
the same emm-type were included to assess reproducibility. RFLP performed on 
different isolates of the same emm-type produced consistently reproducible profiles 
(Figure 3-2 lane 2 and lane 9).  Restriction fragments less than 50 bp could not be 
visualised on the agarose gels and hence were excluded from Table 3-1. No isolates 
refractory to digestion were present among the twenty three emm types digested with 
DdeI (Refer to Appendix C for all the agarose gel electrophoresis results). 
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        1         2         3          4         5         6         7         8         9        10       11      12 
 
 
 
 
 
 
 
 
 
Figure 3-2.  DdeI digests. A 3% agarose gel electrophoresis depicting restriction 
pattern of 10 isolates. Lane 2 emm12,  Lane 3 emm28, Lane 4 emm94, Lane 5 
emm89, Lane 6 emm94, Lane 7 emm94, Lane 8 emm6.4, Lane 9 emm12, Lane 10 
emm4 , Lane 11 emm89. Lane 1 and 12 are molecular markers (Appendix C) 
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Table 3-1.  Restriction profiles obtained following digestion of twenty seven 
different emm types using DdeI  
emm types n=63     Restriction products  (base pairs)   
emm1   3 270 200 180 150 70   
emm2 3 280 150 90 80    
emm3 3 280 200 150 100    
emm4   3 370 100 80 70    
emm6.4 3 200 190 130 100 80   
emm8 3 280 210 90 80    
emm9.2 3 260 170 90 60    
emm12 3 280 240 220 170 120 90 70 
emm22 3 340 150 90 60    
emm44 2 160 150 120     
emm48.1 3 340 110
 Ŋ
 90 80    
emm53   2 250 140 120
 Ŋ
 80    
emm58.2 2 340 160 90 80    
emm73 2 300 150 90 80    
emm75 3 260 100 90
 Ŋ
 80    
emm77 2 240 150 90 80    
emm80   3 320 190 100 70    
emm82 3 250 150 100 80    
emm87   3 340 170 90 70    
emm89   3 270 150 90 80    
emm92 2 490 90 80 50    
emm94 3 250 170 150 100 90   
emm116 3 170
 Ŋ
 90
 Ŋ
      
Ŋ  
doublets  
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3.3.3       Restriction digestion using MboI 
Two to four restriction bands of 90 to 760 bp were observed following digestion with 
MboI. Four emm types were refractory to MboI digestion (Table 3-2).  For emm3, 
emm4 and emm8, the respective bands less than 50 base pairs could not be 
determined following agarose gel electrophoresis (Table 3-2).   
 
                                    1      2      3      4      5      6      7     8      9    10     11   12 
 
 
 
 
 
 
 
 
 
Figure 3-3.  MboI digests. Agarose gel electrophoresis 
depicting 10 GAS isolates. Lane 2 emm12,  Lane 3 emm28, 
Lane 4 emm94, Lane 5 emm89, Lane 6 emm94, Lane 7 
emm94, Lane 8 emm6.4, Lane 9 emm12, Lane 10 emm4 , 
Lane 11 emm89. Lane 1 and 12 are molecular markers.  
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Table 3-2.  Restriction profiles obtained following restriction digest of twenty eight 
different emm types using MboI.  
emm type n=63                    Restriction products  (base pairs)            
emm1 3 520 480 120  
emm2 3 600 220 60  
emm3 3 700 200   
emm4   3 680 210   
emm6.4   3 760 220   
emm8 3 610 200 100  
emm9.2   3 480 340   
emm12 3 440 380 100  
emm22 3 500 340 100  
emm44 2 920*    
emm48.1   3 320 280 240 110 
emm53   2 630 360   
emm58.2 2 990*    
emm73 2 480 270   
emm75   3 350 300 250  
emm77 2 480 180 60  
emm80 3 620 300 50  
emm82 3 960*    
emm87 3 950*    
emm89   3 610 160 120  
emm92 2 420 340 200  
emm94   3 350 290 270  
emm116  3 560 260 100 50 
*No restriction site  
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3.3.4       Restriction digestion using SacI  
Of the twenty three emm types subjected to restriction digestion, only seven could be 
digested with SacI 
 
                    1        2        3        4         5        6        7        8         9       10        11     12   
 
 
 
 
 
 
 
 
 
Figure 3-4.  SacI digests. Agarose gel electrophoresis depicting 10 
GAS isolates. Lane 2 emm12,  Lane 3 emm28, Lane 4 emm94, Lane 5 
emm89, Lane 6 emm94, Lane 7 emm94, Lane 8 emm6.4, Lane 9 emm12, 
Lane 10 emm4 , Lane 11 emm89. Lane 1 and 12 are molecular markers.  
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Table 3-3.  Restriction profiles obtained following digestion of different emm types 
using SacI 
emm types n=63 Restriction products  (base pairs) 
emm1 3 1140*     
emm2 3 880*     
emm3 3 1240*     
emm4   3 800 150    
emm6.4 3 1000*     
emm8 3 950     
emm9.2 3 900*     
emm12 3 1500*     
emm22 3 700 170    
emm44 2 650 260    
emm48.1 3 850 90    
emm53 2 870 100    
emm58.2 2 800 360    
emm73 2 810*     
emm75 3 900*     
emm77 2 750*     
emm80   3 880 100    
emm82 3 950*     
emm87 3 850*     
emm89 3 900*     
emm92 2 950*     
emm94 3 900*     
emm116 3 1000*     
* No restriction site 
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3.3.5       Restriction digestion using HaeIII and HincII.  
Double digestion with HaeIII and HincII produced two to five restriction bands 
between 60 to 830 bp (Table 3-4).  Two emm types were refractory to double digest 
(Table 3-4). 
 
                             1     2     3     4     5     6      7    8     9    10   11   12 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5.  HaeIII and HincII digests. Agarose gel 
electrophoresis of 10 GAS isolates. Lane 2 emm12,  
Lane 3 emm28, Lane 4 emm94, Lane 5 emm89, Lane 
6 emm94, Lane 7 emm94, Lane 8 emm6.4, Lane 9 
emm12, Lane 10 emm4 , Lane 11 emm89. Lane 1 and 
12 are molecular markers.  
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Table 3-4.  Restriction profiles obtained following digestion of different emm types 
using HaeIII and HincII 
emm types n=63 Restriction site Restriction products  (base pairs) 
emm1 3 * 830 220 130  - 
emm2 3 ** 520 350   - 
emm3 3 * 340 300 180 90 - 
emm4 3 *** 750 120   - 
emm6.4   3 ** 720 220 60  - 
emm8   3 *** 470 320 220  - 
emm9.2   3 § 900    - 
emm12 3 * 680 560 220  - 
emm22   3 *** 460 220 Ŋ    - 
emm44 2 *** 340 240 230 130 - 
emm48.1 3 § 800    - 
emm53 2 * 740 220    
emm58.2 2 *** 460 210   - 
emm73 2  420 390    
emm75 3 * 700 220   - 
emm77   3 * 550 240   - 
emm80   3 * 550 240 220   
emm82 3 * 570 280 100  - 
emm87 3 *** 350 280 220 130 - 
emm89   3 *** 350 220 200 130 - 
emm92   2 *** 440 320 200  - 
emm94   3 * 320 280 230 130 - 
emm116   3 * 740 200   - 
* Restriction site for HaeIII 
** Restriction site for HincII  
*** Restriction site for both HaeIII and HincII 
§ No restriction sites for both HaeIII and HincII 
Ŋ  doublets  
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3.4       Discussion  
The twenty three emm types subjected to RFLP could be differentiated by restriction 
profiles (Table 3-1, 3-2 and 3.3; Figure 3-2, 3-3, 3-4 and 3-5).  Three restriction 
enzymes, DdeI, MboI or SacI, were used for single digestion and a combination of 
HaeIII and HincII for double digests. None of the emm types in this study were 
refractory to digestion with DdeI, and all the profiles generated by DdeI could be 
distinguished from each other. These results correlate with those seen in another 
study which characterised GAS using DdeI [66].  During a scarlet fever outbreak in 
Mexico, RFLP using DdeI identified five emm types in 40 GAS isolates which 
correlated with sequencing results [66].  Sequencing confirmed the emm types as 
emm2, emm12, emm1, emm22 and emm89 [66].  
 
Nineteen different emm types digested with MboI produced unique and readily 
distinguishable restriction profiles while four emm types could not digested (Table 3-
2).  Interestingly only seven emm types contained restriction sites recognised by SacI 
(Table 3-3).  However, for those emm types which were readily digested by SacI, the 
profiles were unique enough to deduce the differences. To the best of the author’s 
knowledge, there are no other studies reporting on either MboI or SacI digests.   
 
Following double digests with HaeIII and HincII (Table 3-4), two emm-types were 
not digested by either HaeIII and HincII (Table 3-4).  However, in the remaining 
twenty one emm-types, the restriction profiles were discriminatory enough to identify  
the different emm types (Table 3-4),  consistent with previous studies [66, 80, 83].  
The study by Perea-Mejia during the scarlet fever outbreak in Mexico used HaeIII 
and HincII to segregate forty isolates into five emm types [66] while a study by Beall 
[80] observed restriction profiles that were able to distinguish 32 emm types from 
945 geographically diverse clinical isolates [80].  The 32 restriction profiles 
represented different emm types that had previously been identified using sequencing 
(emm typing) [80].  
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Restriction fragment length polymorphism has been useful in differentiating and 
grouping similar emm types [66, 80].  Representatives of the emm types in this study 
could be segregated based on their respective restriction profiles.  These observations 
have also been seen in other studies which used RFLP to identify similar emm types. 
As previously mentioned, the study by Perea-Mejia was able to group 40 isolates into 
five groups based on restriction profile produced following digestion with DdeI [66].  
Similarly, RFLP was useful in another study investigating 106 GAS isolates [71].  
Although a different enzyme (AluI) from those recommended by the CDC was 
utilised in the later study, nineteen different profiles distinct to different emm types 
were identified [71].  More impressively is the study by Beall which identified 32 
emm types from 945 geographically diverse clinical isolates by RFLP [80], 
illustrating the ability of this relatively simple technique to distinguish the M-
proteins.  Hence RFLP can be used to differentiating emm types, particularly when a 
large number of isolates are involved.  This minimizes the cost of further 
investigations such as sequencing. 
 
The sequencing part of emm typing assay is the major limiting factor in developing 
countries.  The emm typing assay requires generation of sequences in order to 
differentiate the N-terminal of the M-protein [168], most of the developing countries 
lack resources or sequencing facilities to carry out this most crucial part of the 
technique.  Sequencing machines and associated reagents are costly thus posing a 
challenge to laboratories lacking resources.  Other molecular typing techniques such 
as MLST and PFGE are laborious and require intense data analysis [72].  Similar to 
emm typing, MLST is a sequencing based technique. While PFGE lacks a 
sequencing step [72] other the limitations associated with PFGE includes 
standardisation, turn-around time of four to five days [179] and inter laboratory 
variation in results.  
 
In this study, twenty three emm types subjected to RFLP were readily digested by 
MboI, DdeI, HaeIII and HincII producing distinct restriction profiles.  Although the 
emm typing techniques remains the gold standard in molecular epidemiology of 
GAS, RFLP can be an alternative assay in identification of emm types with similar 
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restriction patterns.  It is evident that RFLP is ideal in segregating different emm 
types based on distinct profile.  The restriction product sizes produced in this study 
can be useful in identifying local emm types, although studies using a greater range 
of local emm types may be needed to fully validate this approach. 
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Chapter Four:  C-repeats 
 
C-repeats of the M-protein contain potential vaccine candidates 
conserved among GAS strains 
 
4.1       Introduction  
As elaborated in Chapter Two (2.1), the M-protein consists of regions A to D (Figure 
2.1).  The C region is conserved across GAS strains and contains potential vaccine 
candidates which may be an alternative to the M-protein specific vaccines [8].  The 
C-repeats of the M-protein, in which the vaccine candidates feature, are conserved 
sequences located on the C region.  
 
Studies investigating the conserved region of the M-protein preferably utilise amino 
acid sequence analysis in place of nucleotides.  This is due to the fact that amino acid 
sequences are more conserved than nucleotide sequences as a result of genetic code 
degeneracy.  Of the sixty-one codons that make up the genetic code, there are only 
twenty amino acids (Appendix D).  Therefore, two different codons may code for the 
same amino acid e.g., valine is coded by the codons GTT, GTC, GTA or GTG.  
Hence, protein sequences may remain conserved even though their respective 
nucleotide sequences may harbour variations.  Different bioinformatics tools are used 
to align the protein sequences in order to identify the conserved regions [180, 181].  
The M-protein contains at least three conserved sequences, C1, C2 and C3 [145, 180, 
181].  These repeats are identified following multiple alignment of the protein 
sequence. 
 
A region of one of the C-repeat sequences, J14, has been used in the construction of 
a vaccine target that is conserved among GAS strains.  Three other J14 like 
sequences, namely; J14.1 J14.2 and J14.8, have also been identified as potential 
vaccine candidates [181].  The full amino acid sequence of J14 in the vaccine is 
KQAEDKVKASREAKKQVEKALEQLEDKVQC [182].  The amino acids in bold are M-
protein specific while the flanking sequences, underlined, are derived from yeast 
(GCN4) and assist in achieving the helical folding and conformational structure of 
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the M-protein [182]. Recently, antibodies against the J8 region have been raised in 
mice, and provides strong potential as a vaccine candidate given the cross-protective 
immunity against GAS isolates containing J14.0 and J14.[145]1.     
 
Geographical differences in the distribution of the emm types and lower coverage in 
developed countries shown by M-protein vaccines targeting the hypervariable region 
(N-terminus, block A) have encouraged a focus on the conserved region as a 
potential vaccine target.  The geographical differences among dominant emm types 
from different continents, as presented in Chapter One (Table 1-1), result in the type 
specific M-protein based vaccine having less coverage in developing countries as 
discussed in 2.4.  The J14 vaccine is efficacious and does not cross-react with host 
tissues, as elaborated in Chapter One (1.6.2) [145, 181].  This part of the study aims 
to describe the sequences of the C-repeats of the M-protein as potential J14 vaccine 
targets that are shared across GAS strains. 
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4.2       Experimental protocol 
4.2.1     Study population, identification of β-haemolytic streptococci and 
amplification of the emm gene 
Sixty three isolates (used in Chapter Three)  representing twenty three emm types 
were included for analysis of the conserved region of the M-protein.  Where 
available, only emm types represented by more than a single isolate identified in 
Chapter Two (Table 2-2) were included for C repeat analysis. The DNA isolation 
and amplification were carried out as elaborated in Chapter Two (2.2.1-2.2.6).  
 
4.2.2       Sequencing the C-terminus of the emm gene 
Following purification of the amplified emm gene (2.2.6), DNA was quantified using 
the NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA).  
In order to sequence the C-repeat regions of the M-protein, primer 2 [10], the reverse 
primer utilised in the amplification of the emm gene [10], is used.  Primer 2 (Table 2-
1) was prepared to 1.1 ng/µl and used in the sequencing reaction.  The amplicons 
were analysed and edited using BioEdit v7.0.9 (Ibis Biosciences, USA). 
 
4.2.3       Translation of M-protein sequences into amino acid 
Since the reverse primer (primer 2) runs from the 3´ to 5´ direction and was utilized 
to generate the sequences of the C-repeat region, the reverse complement sequence 
was generated and then translated into the amino acid sequence using BioEdit v7.0.9 
(Ibis Biosciences, USA).   
 
4.2.4       Identification of the C-repeats within the M-protein sequences 
The Multiple Em Motif Elicitation (MEME) online program aligns nucleotides or 
amino acid sequences in order to identify conserved regions within the sequences 
[183].  Depending on the number of conserved regions, specified by the investigator, 
the MEME program generates sequence alignments of each of the conserved region 
followed by generation of a sequence LOGO [183].  A sequence LOGO generated by 
MEME is the position-specific probability of a nucleotide or amino acid appearing in 
a predicted position within a specific conserved region.   
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The MEME online program was specified to identify three C-repeats in all the 
twenty three emm types, based on previous studies’ reports [143, 145].  Sequences in 
FASTA format (4.2.3), were uploaded onto the MEME website and submitted for 
analysis, (http://meme.sdsc.ed/meme/cgi-bin/meme.cgi 16 February 2012). 
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4.3       Results 
4.3.1       Multiple sequence alignment 
Multiple sequence alignment of the conserved region was generated using MEME 
sequence alignment.  Three different sequence alignments representing three C-
repeats, C1, C2 and C3, were generated (Appendix D).  Only sequences containing a 
respective C-repeat appeared in the alignment. The sequences were arranged based 
on their p-value.  The p-value of the sequence alignment indicates the degree of 
motif match and not the degree of conservation of the sequences (Refer to Appendix 
D for sequence alignment results). 
 
4.3.2       Identification of conserved sequences in C region of the M-protein 
The MEME online program identified three C-repeat sequences in sixteen emm 
types, while seven emm types had only two C-repeats (Table 4-1).  Amino acid 
alignments depict sequence variations within individual conserved regions 
(Appendix D).  The first conserved region, C1, showed more sequence variation than 
the second and third conserved regions. The region  C2 and C3, consisted mainly of 
the J14 and J14.1 variants, respectively.  All the emm types included in this study 
contained either the J14 or J14-like sequence.  
 
4.3.3       The MEME sequence LOGO 
A MEME sequence LOGO was generated based on the sequences submitted to the 
MEME online program.  Three different LOGO were generated, each for the three 
conserved regions, C1, C2 and C3 (Figure 4-1).  Each LOGO contained sequences of 
the specific conserved region.  The height of the letters in the LOGO depends on 
sequence variation within individual conserved region (Table 4-1). 
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Figure 4-1.  Sequence LOGO of three C-repeats. Each logo contains conserves 
sequences of the J14 or J14-like sequences. Each single letter amino acid height 
stands for a probability of that particular amino acid being located in the specified 
position. 
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Table 4-1.  C-repeats sequences 
emm type n=63 C1-repeat C2-repeat C3-repeat 
emm1 3 J14.2 J14.2 J14 
emm2 3 J14.29 J14.12 J14.1 
emm3 3  J14.2 J14 
emm4 3 J14.36 J14.12 J14.1 
emm6.4 3  J14.2 J14 
emm8 3 J14.8 J14.1 J14.1 
emm9.2 3  J14.1 J14.1 
emm12 3 J14.8 J14.2 J14 
emm22 3  J14.41 J14.1 
emm44 2 J14.8 J14.1 J14.1 
emm48.1 3 J14.36 J14.1 J14.1 
emm53 2 J14.2 J14.2 J14 
emm58 2 J14.29 J14.1 J14.1 
emm73 2  J14.29 J14.1 
emm75 3 J14.36 J14.1 J14.1 
emm77 2  J14.8 J14.1 
emm80 3 J14.2 J14.2 J14 
emm82 3 J14.72 J14.1 J14.1 
emm87 3  J14.1 J14.1 
emm89 3 J14.29 J14.1 J14.1 
emm92 2 J14.29 J14.1 J14.1 
emm94 3 J14.12 J14.1 J14.1 
emm116. 3 J14.2 J14.1 J14.1 
J14       ASREAKKQVEKALE 
J14.1    ASREAKKKVEADLA 
J14.2,   ASREAKKQVEKDLA 
J14.8    ASRAAKKELEAEHQ 
J14.12  ASRAAKKELEAKHQ 
J14.29  ASRAAKKDLEAEHQ 
J14.36  ASRAAKKELEANHQ 
J14.41  ASRAAKKKVEADLA 
J14.72  ASRAAKKGLEAEHQ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
68 | P a g e  
 
4.4       Discussion 
The C-repeat region of the M-protein is highly conserved across GAS strains thus 
making it potentially an ideal vaccine target for multiple GAS strains.  Sixty three 
GAS isolates, representing twenty three emm types were analysed to characterise the 
C-repeat regions.  The C1-repeat of the M-protein contains more sequence variation 
compared to both C2 and C3.  Among the twenty three emm types investigated in 
this study, there was sequence variation in the C1 region from different emm types 
(Table 4-1).  The J14 sequence was not identified in region C1 of any of the 
sequences included in this study.  These results observed from C1-repeats accords 
with the high level of sequence variation reported in the studies conducted by Vohra 
and Smeesters, respectively [145, 180].   
 
Within the C2 region, thirteen different emm types contained J14.1.  Other studies 
have also found a variety of sequences in the C2, however, J14.1 was the most 
common [145, 180].  Twenty-three out of thirty-one emm types investigated by 
Vohra corresponded to J14.1 while six had J14.4 sequences and one emm105 isolate 
harboured J14.8 [145].  Similarly, J14.1 (30 out of 51 emm types) was dominant in 
C2 in a study by Smeesters, followed by J14.2 [180].  The C2 region reported by 
Smeesters showed higher sequence variation compare to this study and that of Vohra.  
However, it is important to note that the number of emm types investigated in this 
study (23) and those reported by Vohra (31) were less than those reported by 
Smeesters (51). 
 
The C3 region, which is more proximal to the cell, harbours sequences 
corresponding to J14 and J14.1 [145, 180].  Six emm types in this study harboured 
sequences corresponding to the J14 sequences while seventeen emm types contained 
the J14.1 sequence.  The presence of either J14 or J14.1 is emm type specific.  (Table 
4-1).  These results are similar to other studies that have investigated the conserved 
region of GAS [145, 180, 181].  Smeesters as well as Vohra have reported the 
presence of predominately J14 and J14.1 from the C3 region among the isolates 
investigated.  In the study by Smeesters, eighteen emm types harboured sequences 
corresponding to J14, thirty emm types corresponded with the J14.1 sequence, two 
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emm types corresponded to J14-R11 and emm78 contained a sequences different 
from J14 [180].  Similarly, the study by Vohra also found dominantly the presence of 
J14 or J14.1 in C3 being emm type specific [145].  Twenty-one out of thirty-one emm 
types investigated harboured sequences corresponding to J14.1 while the other ten 
corresponded to J14 [145].  Based on the results observed in this study (Table 4-1) 
and those reported by both Smeesters [180] and Vohra [145], respectively, C3 
dominantly harbours sequences corresponding to J14.1 while a few emm types 
contain J14. 
 
C3 is the most conserved region, relative to C2 and C1, with the degree of 
conservation increasing as one moves more proximally toward the cell.  As it is 
evident from sequence alignment (Appendix D) and data presented on Table 4-1, the 
C3 region contains predominantly J14.1 whereas C2 has decreased sequence 
conservation, mainly J14.1 and other sequences (Table 4-1).  Also, as previously 
elaborated, C1 displayed the most diverse sequences. This observation has also been 
seen by another study which identified C1 as the most diverse of the three C-repeats 
[181], similarly, all the other studies investigating the conserved region of the M-
protein accords these similar observations [71, 145, 180]. Since C1 is less proximal 
to the cell compared to C2 and C3, one can suggest that the degree of sequence 
conservation of the M-protein decreases as one moves away from the cell. This is 
borne out by the fact that the N-terminus of the M-protein, which is known for its 
degree of hypervariety, is situated distally while the C-repeats are proximal to the 
cell,. 
 
The four J14 sequences that are potential vaccine candidates are J14, J14.1, J14.2 and 
J14.8 [145, 180].  Sequences corresponding to these four vaccine candidates were 
identified in all the twenty three emm types investigated in this study (Table 4-1).  
The C3-region described previously harboured J14 and J14.1 while J14.2 was 
identified in the C2 region.  The C3 region is highly conserved and harbours the J14 
and J14.1 sequences [145], hence a vaccine designed to target the J14 or J14-like 
peptides can potentially induce protective antibodies that can protect against multiple 
GAS serotypes.  This study and the studies conducted by Smeesters and Vohra, 
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respectively, have shown the presence of the J14 and J14.1 sequence among different 
emm types (Table 4-1) [145, 180].  The four vaccine candidates were identified 
among different emm types from different regions of the globe suggesting that 
protection by J14 or J14.1 based vaccines can be effective against multiple GAS 
strains from different regions of the globe. 
 
The 26-valent type specific M-protein vaccines only offer protection against GAS 
strains included in the respective vaccine [46, 48], a property which makes these 
vaccines less favourable in some developing countries.  With more than 220 emm 
types currently known and only 30 emm types included in the latest 30-valent 
vaccine [140], this raises concerns over the coverage of the type-specific vaccines in 
developing countries.  However, a vaccine based on the conserved J14 is not M-
protein specific due to the conserved sequences, observed in the C3-repeat (Table 4-
1) [145, 180].  Hence this vaccine target can be an alternative to multiple GAS 
strains currently known, regardless of the prevalent emm type in a particular setting.  
Nevertheless, there are considerable concerns regarding their immunogenicity with 
consistent results not being observed between laboratories [184]  
 
In summary, twenty three emm types analysed in this study harboured either the J14 
or J14.1 sequences which are both potential vaccines candidates.  Translating this 
into the vaccine perspective means that a vaccine designed to target the conserved 
region of the M-protein may be more ideal due to the level of conservation of this 
region across GAS strains.  The J14 vaccines have shown promising results in 
protecting against GAS infections.  Therefore, regarding J14 or J14.1, this study has 
shown a lack of M-protein specificity and geographical differences, making this 
vaccine candidate ideal in developing countries where high diversity of emm types 
exists. 
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Chapter Five: Streptococcal pyrogenic exotoxin 
 
Streptococcal pyrogenic exotoxin gene profiles among Group A streptococci in 
Cape Town, South Africa 
 
5.1       Introduction 
Streptococcal superantigens (SAg) are prominent GAS virulent factors.  As 
previously elaborated in Chapter One (1.1.3), eleven different streptococcal 
pyrogenic exotoxins (SPE); namely; SPEA, SPEC, SPEG, SPEH, SPEI, SPEJ, 
SPEK, SPEL, SPEM, streptococcal mitogenic exotoxin Z (SMEZ) and streptococcal 
superantigen A (SSA) have been described [27, 30, 34, 40, 185].  Considering the 
existence of the eleven SAg, detection of these genes can be laborious, time 
consuming and costly. Hence, different studies have opted for different molecular 
techniques for detection of these SAgs; conventional, multiplex or real-time PCR 
[27, 30, 42]. 
 
Conventional PCR has been widely used in the study of SAgs although this assay is 
laborious and time consuming especially when a different reaction is required for 
each gene [30, 32, 37, 54, 62].  However, most molecular SAg studies opt for 
detection of a single gene per reaction due to the number of parameters that would be 
needed to detect multiple genes [186, 187].  
 
Multiplex PCR, devised in 1988 [188], detects more than two genes simultaneously, 
saving time, minimizing labour and is relatively cheaper than either conventional or 
real-time PCR [186, 187].  Multiplex PCR assays have been optimized to detect up 
to nine SAg genes  (speA, speB, speC, speF, speG, speH, speJ, smeZ and ssa) 
simultaneously [42].  However, due to different conditions that may be required by 
individual primers, appropriate conditions that will accommodate all the primers 
need to be ascertained.  A study by Lingtes investigating thirteen SAg genes opted 
for two sets of multiplex PCR for successful amplification [27].  The first set 
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contained spea1-3+5, spec, speg, spej, spek and spel while the second set consisted 
spea1-4, speh, spei, spem, ssa and smez.  These two sets of genes were segregated 
due to the complexity of the multiplex PCR setup, in which primers pairs, reagent 
concentrations and PCR cycling conditions require common conditions to 
successfully amplify all the genes [186, 187].  Although multiplex PCR is more 
appropriate in detection of multiple genes simultaneously, the difficulty of this 
method lies in determining the optimal combination of reagents, primer 
concentrations and cycling conditions.  However, successfully optimised multiplex 
PCR assays can save time and are relatively cheap. 
 
Real-time PCR is the most sensitive method for detecting nucleic acid and hence 
may be ideal in SAg investigations. Real-time PCR, which amplifies and quantifies 
the target gene simultaneously, has also been applied in detection of SAg [27].  
Interestingly, the multiplex real-time PCR was also able to identify a strain which did 
not harbour any SAg genes among the SAg investigated [27].   
 
As is the case with other aspects of GAS in South Africa, there is lack of data on 
streptococcal superantigens.  Hence the primary aim of this component of the study 
was to describe the distribution of SAg in association with emm types from patients 
with symptomatic pharyngitis as well as asymptomatic GAS carriers, using 
conventional multiplex PCR. 
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5.2       Experimental protocol  
5.2.1       Study population and preparation of genomic DNA 
A total of 98 GAS isolates representing 23 emm types were selected for investigation 
of SAg using conventional multiplex PCR. The same 23 emm-types that were 
analysed  in Chapter 3 were chosen for this analysis. However, for this analysis we 
elected to analyse up to seven isolates (if possible) belonging to an individual emm-
type in order to assess the degree of variation of the supernatigen profiles among 
different isolates belonging to the same emm-type.  The selected samples included 
isolates representing more than a single isolate (Table 2-2). All the emm types 
identified represented by a single isolate were excluded for analysis (Table 2-2).  
Among the 98 isolates, 75 were obtained from symptomatic and 23 asymptomatic 
pharyngeal isolates (2.2.1).  The genomic DNA investigated was obtained as 
described in 2.2.3.  Among the 98 isolates, 75 were obtained from symptomatic and 
23 asymptomatic pharyngeal isolates (2.2.1).  The genomic DNA investigated was 
obtained as described in 2.2.3.  
 
5.2.2       Single-plex PCR assay 
PCR assays for detection of eight genes (speA, speB, speC, speF, speG, speH, speJ 
and smeZ) were performed as single reactions in order to ensure appropriate 
amplification of each gene.  Each PCR reaction included a final concentration of 1X 
buffer, 2.5 mM MgCl2, 0.4 mM dNTP, 0.2 µM of primer and 3.5U of SuperTherm 
Taq (JMR, Holdings, London UK) in a final volume of 50 µl as described by 
Schmitz [42], except for the primer concentrations.  All primers were synthesized at 
the Department of Molecular and Cell Biology, University of Cape Town, South 
Africa. Respective primer sequences and expected product sizes are presented in 
Table 5-1.  
 
The Applied Biosystems 2720 Thermocycler (Applied Biosystems, Carlbad, CA, 
USA) was used to amplify the SAg genes using PCR cycling conditions described by 
Schmitz [42].  Initial denaturation at 96ºC for a minute was followed by 30 cycles of 
denaturation at 96ºC for 50 seconds, annealing at 46ºC for 65 seconds and extension 
at 72ºC for 75 seconds.  Final extension was carried out at 72ºC for 5 minutes.  
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Amplification products were analyzed using agarose gel electrophoresis in a 2% 
agarose gel (2.2.5) for 4 hours.  
 
5.2.3       DNA sequence analysis of amplified products 
Following PCR amplification of each of the eight genes, the amplicons were purified 
as previously described (2.2.6), quantified and submitted for DNA sequencing as 
elaborated previously (2.2.7), using the appropriately diluted forward primers (Table 
5.1).  The sequence data were analysed using BioEdit v7.0.9 (Ibis Biosciences, USA) 
and compared to existing sequences by BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi 28th November 2011). 
 
Table 5-1.  Primers sequences used for amplification of streptococcal 
superantigens 
Target 
genes 
Primers Primer sequences [42] Expected product sizes 
speA  Forward TAA GAA CCA AGA GAT GG 248 
 Reverse ATT CTT GAG CAG TTA CC  
speB  Forward AAG AAG CAA AAG ATA GC 955 
 Reverse TGG TAG AAG TTA CGT CC  
speC  Forward GAT TTC TAC TTA TTT CAC C 584 
 Reverse AAA TAT CTG ATC TAG TCC C  
speF  Forward TAC TTG GAT CAA GAC G 782 
 Reverse GTA ATT AAT GGT GTA GCC  
speG  Forward AGA AAC TTA TTT GCC C 155 
 Reverse TAG TAG CAA GGA AAA GG  
speH  Forward  AGA TTG GAT ATC ACA GG 416 
 Reverse CTA TTC TCT CGT TAT TGG  
speJ  Forward ATC TTT CAT GGG TAC G 535 
 Reverse TTT CAT GTT TAT TGC C  
smeZ  Forward TAA CTC CTG AAA AGA GGC T 391 
 Reverse CAT TGG TTC TTC TTG ATA AG  
Spe - Streptococcal pyrogenic exotoxin, SmeZ – Streptococcal mitogenic exotoxin Z 
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5.2.4       Multiplex PCR 
During optimisation of the multiplex assays, a number of parameters were varied in 
order to determine the optimum conditions for a multiplex PCR assay. 
 
5.2.4.1      MgCl2 
Three reagents utilised in PCR reaction, Taq polymerase, dNTPs and primers, 
require magnesium at an optimum concentration for optimal PCR fidelity [187].  
Alteration in MgCl2 concentration increases sensitivity and specificity of the reaction 
[189], hence, MgCl2 was tested at a serial increments of 0.5 mM from 2 mM to 3.5 
mM while maintaining the concentrations of other reagents (dNTP, Taq polymerase 
and primer concentrations). 
 
5.2.4.2      dNTP 
For optimum PCR reaction, a proper balance betwe n MgCl2 and dNTP is essential, 
as excessive dNTPs will inhibit the reaction [187].  The dNTPs work optimally at 0.2 
mM when MgCl2 concentration is between 1.5 and 2 mM [186, 187], thus, dNTP 
were tested at a serial increments of 0.1 mM from 0.2 to 0.5 mM.  As the anticipated 
PCR product sizes ranged from 955 to 155 base pairs, a high dNTP concentration 
was required for complete elongation of double stranded DNA. 
 
5.2.4.3      Primers  
Primer concentrations and other PCR parameters such as melting and annealing 
temperatures play crucial roles during PCR [186, 187].  For optimum PCR 
amplification, depending on different loci, final primer concentrations of between 
0.04 to 0.6 mM may be required for successful PCR amplification [186, 187].  In this 
study, all primers were tested at initial 0.2 mM and increased gradually by 0.1 mM 
up to a maximum of 0.7 mM if necessary.  
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5.2.5       Detection of streptococcal superantigens using optimised multiplex 
PCR assay 
Molecular graded water (Promega, USA) was calculated to bring the final reaction 
volume to 50 µl following addition of 1X buffer, 2.5 mM MgCl2, 0.4 mM dNTP, and 
3.5U of SuperTherm Taq polymerase (JMR Holdings, London, UK).  Primer 
concentrations utilized are presented in Table 5-2.  PCR cycling conditions were 
identical to those utilized in detection of individual genes (5.2.2).  Agarose gel 
electrophoresis for detection of amplification products was performed as described in 
5.2.2. 
 
Table 5-2.  Multiplex PCR assay reagents  
Multiplex Buffer MgCl2 dNTPs Primer speA, speC, 
speG, speH, smeZ 
Primer 
speB, speJ 
Primer 
speF 
Initial  1X 0.5 mM 0.4 mM 0.2 µM 0.2 µM 0.2 µM 
Optimised  1X 0.5 mM 0.4 mM 0.2 µM 0.3 µM 0.63 µM 
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5.3       Results 
5.3 1       Amplification and sequencing of individual superantigen genes 
Single-plex PCR assays were performed on 10 randomly selected isolates and each 
of the eight genes were amplified separately from at least one of the isolates.  The 
DNA sequences of the amplification products showed sequence homology of at least 
99% with published sequences of the respective genes (Appendix E).  This was taken 
as evidence that the primers were amplifying the appropriate genes.  
 
5.3.2       Positive control 
No single isolate of the 10 randomly chosen isolates contained all eight genes.  
However, based on the results of single-plex assay, two isolates that between them 
contained all the eight genes investigated were identified.  The first isolate contained 
seven genes, SpeA, SpeB, SpeC, SpeF, SpeG, SpeJ and SmeZ while the second isolate 
contained four genes, SpeB, SpeF, SpeG and SpeH.  These two isolates were used as 
positive controls for all subsequent optimisation assays.  
 
5.3.3       Initial multiplex PCR 
In the initial multiplex PCR assay, only four genes, SpeA, SpeC, SpeG and smeZ, out 
of the seven genes expected from the first control were amplified while all the four 
anticipated genes from the second control, SpeB, SpeF, SpeG and SpeH, were 
amplified. However, SpeB, SpeF, SpeG and SpeH genes from the second control 
could were amplified but produced faint bands following agarose gel electrophoresis 
observation (Figure 5-1). 
 
5.3.4       Optimum reagents and primer concentrations for multiplex PCR  
Increasing the MgCl2 concentration by 0.5 mM increased the PCR product yield with 
the best yield observed at 2.5 mM, hence this concentration was adopted.  Serial 
increments of dNTP concentration by 0.1 mM did not result in any increase in 
amplification products, however, previous studies had observed improved product 
yield with MgCl2 and dNTP concentrations of 2 mM and 0.4 mM, respectively, thus 
a final  dNTP concentration of 0.4 mM was adopted [186, 187].  Optimisation of 
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individual primer concentrations had the most dramatic impact on the multiplex 
PCR. Increasing the concentrations of primers for speF, speB and speJ, which did 
not amplify in the initial attempt, (Figure 5-1), resulted in the amplification of speF, 
speB and speJ genes (Figure 5-2).  Primers for SpeA, SpeC, SpeG, speH and smeZ 
genes were kept at the initial 0.2 µM while optimum yield of speF was observed with 
0.63 µM (from the initial 0.2 µM) and both speB and speJ were amplified using 0.3 
µM of primers (Table 5-2). 
 
 
                       1            2              3              4             5              6 
 
 
 
                                                                                                                            1000 bp   
 
 
 
                                                                                                                              100 bp 
 
 
Figure 5-1. Initial multiplex PCR for the amplification of 
eight streptococcal pyrogenic exotoxins genes. Lane 1 and 
6 are molecular markers (HyperLadder VI, Appendix B). 
Lanes 2 posiive control 1, lane 3 positive control 2 and lane 4 
sample 1 and lane 5 negative control (H2O).  
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Figure 5-2. Agarose gel electrophoresis f llowing multiplex 
PCR of eight streptococcal pyrogenic exotoxins. Lane 2 and 12, 
molecular marker, Lane 1 is a negative control while lane 3 and 4 
are positive controls. 
 
5.3.5       Detection of streptococcal pyrogenic superantigens using multiplex 
PCR 
Out of the 98 isolates tested, 21 different superantigen profiles were obtained.  These 
profiles were distributed across different emm types (Table 5-3).  The most 
commonly detected gene was speG from 98 isolates (94%) and the least frequenly 
detected was speA, from 18 isolates (17%) (Table 5-3).  None of the superantigen 
genes were found in six out of the 98 isolates.   
 
There was a higher prevalence of some of the superantigen genes in isolates from 
symptomatic cases compared to asymptomatic cases (Figure 5-3), most notably speA, 
speB, speC, speF, speH and speJ. However, the difference was only statistically 
signifuicant for speC. .  SpeC was detected in 71% of the isolates from symptomatic 
patients compared to 4% of the isolates from asymptomatic patients. 
 
 
speB 
speF 
speH 
speJ 
smeZ 
speC 
speG 
speA 
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Figure 5-3.  The distribution of amplified SAg gene among pharyngeal isolates. 
The total number of amplified genes are indicated in brackets. 
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Table 5-3.  emm types and their respective superantigen profiles. 
   Superantigen 
emm 
types 
Superantigen  
profile 
n 
 
SpeA SpeB SpeC SpeF Spe
G 
Spe
H 
SpeJ Sme
Z 
emm48.1 A 2 - - - - + - - - 
 B 3 - + + + + + + - 
 D 5 - + + + + - + + 
 E 1 - + + + + + + + 
 F 1 + + + + + - + + 
emm12 A 3 - - - - + - - - 
 B 3 - + + + + + + - 
 G 3 + + + + + + + - 
 H 1 - - - - + + + - 
 P 1 - - - - + + - - 
emm4 B 1 - + + + + + + - 
 C 1 - + + + + - + - 
 D 5 - + + + + - + + 
 M 1 + + + + + - + - 
 N 1 - + + + + - - + 
 R 1 - - - - + - - + 
 S 1 - + - + + - + + 
emm89 A 1 - - - - + - - - 
 B 1 - + + + + + + - 
 C 1 - + + + + - + - 
 F 1 + + + + + - + + 
 H 1 - - - - + + + - 
 K 1 - + - + + + + - 
emm94 B 2 - + + + + + + - 
 C 1 - + + + + - + - 
 E 1 - + + + + + + + 
 F 1 + + + + + - + + 
 G 1 + + + + + + + - 
 P 1 - - - - + + - - 
 T 1 - + - + + + - - 
emm75 C 1 - + + + + - + - 
emm1.0 A 1 - - - - + - - - 
 E 1 - + + + + + + + 
 F 2 + + + + + - + + 
emm22.0 B 2 - + + + + + + - 
 C 3 - + + + + - + - 
 E 1 - + + + + + + + 
 G 1 + + + + + + + - 
emm2.0 A 3 - - - - + - - - 
 C 1 - + + + + - + - 
emm9.2 A 3 - - - - + - - - 
 C 3 - + + + + - + - 
 O 1 - + + + + - - - 
emm87 A 2 - - - - + - - - 
emm116 J 2 + + - + + - + + 
emm82.0 A 1 - - - - + - - - 
emm3 Q 1 + + + + + - - + 
emm6.4 A 1 - - - - + - - - 
 E 1 - + + + + + + + 
emm8.0 D 1 - + - + + - + + 
 F 1 + + + + + - + + 
 I 1 - + - + + + + + 
emm44.0 G 1 + + + + + + + - 
emm53.0 E 1 - + + + + + + + 
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emm58.2 A 1 - - - - + - - - 
 L 1 + + + - + - + + 
emm73 B 1 - + + + + + + - 
emm92 E 1 - + + + + + + + 
 H 1 - - - - + + + - 
emm28.0 D 1 - + + + + - + + 
emm33 E 1 - + + + + + + + 
emm77 I 1 - + - + + + + + 
emm64 U 1 - - - - + - + - 
emm80 F 1 + + + + + - + + 
Emm49 A 1 - - - - + - - - 
emm118.
1 
A 1 - - - - + - - - 
emm75 A 1 - - - - + - - - 
st2002.2 B 1 - + + + + + + - 
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5.4       Discussion  
Among the 98 GAS isolates investigated, the most common SAg was speG, present 
in 94% of the isolates while the least frequently detected SAg was speA in only 17% 
of the isolates (Table 5-3 and Figure 5-3).  The speG gene is one of the three 
chromosomally coded genes [41] as elaborated in Chapter One (1.1.3) hence it is 
anticipated that it would be present in all the isolated investigated. 
 
The other two chromosomally coded genes [41], SpeJ and SmeZ  were present in 
67% and 35% isolates, respectively.  Up to 100% detection of speG has been 
reported by some studies [34, 41, 190, 191] suggesting chromosomal coding, while 
other studies have documented this gene in 90% [30] and 84.1% [37] of the isolates.  
The other chromosomally coded genes, speJ and smeZ, were detected in 33.3% and 
91.7% of the isolates by Rivera [37], respectively, while Commons detected these 
genes in 51% and 95% of the isolates, respectively [30, 37].  These results accord 
with those reported by Schmitz which did not identify speJ and smeZ in all the 
isolates investigated [42].  The gene for smeZ is believed to have 23 alleles [37] 
hence the primer designed for a single allele could play a crucial role in the success 
of the multiplex PCR.  Another factor that could interfere with the detection of these 
genes is the genomic DNA extraction method utilized.  The study by Commons 
reported that the DNA extraction method may interfere with PCR amplification [30].  
The authors observed that PCR amplification of DNA extracted by mechanical 
agitation was much more sensitive than PCR amplifying DNA extracted by the 
boiling method (heating at 100ºC for 10 minutes) [10, 30].  
 
Six isolates in this study lacked all the eight SAg genes, speA, speB, speC, speF, 
speG, speH, speJ and smeZ, despite attempts to amplify speG and smeZ in single-
plex reaction.  The closed-tube multiplex PCR designed by Lingtes also identify a 
strain without any SAg gene [27].  The multiplex PCR was designed to detect two set 
of genes coding spea1-3+5, spec, spej, spek, speal and speg in the first set and the 
second set contained spea1-4, speh, spei, spem, ssa and smez, however genes coding 
speB and speF were not included [27].  Another study conducted by Rivera also 
identified an isolate with no SAg genes when nine genes, namely; speA, speB, speC, 
speH, speI, speJ speM, ssa, and smeZ, were investigated [37]. 
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Twenty one different SAg profiles were identified among 98 GAS isolates (Table 5-
3).  Twenty one of the isolates (20%) contained only speG while the rest of the 
profiles were evenly distributed among the isolates.  The distribution of the SAg 
profiles showed no association between any particular profile and isolates from 
symptomoatic versus asymptomatic patients.. Other studies have documented 
associations between SAg and particular diseases.  For instance, speA and speC have 
both been associated with scarlet fever and STSS [29, 31-33].  A study conducted by 
Schmitz, observed no connection between GAS diseases and a particular SAg profile 
[42], with no significant (P>.01) differences between invasive, wound and 
pharyngeal isolates. Thus, according to Schmitz, possession of a particular SAg 
profile does not characterise GAS isolates [42].  In Japan, a study investigating 316 
GAS isolates from invasive (bacteremia and toxic shock-like syndrome) and non-
invasive infections (mucosa, pharynx, tonsils, respiratory track, ears, nose, vagina, 
stool and urethra) also found no correlation between SAgs and GAS isolation sites 
[54].   
 
Some emm types are associated with distinct SAg profiles [37].  The twenty one SAg 
profiles observed in this study did not show any association with the predominant 
emm types (emm48, emm12, emm4 and emm89) (Table 5-3).  There is a random 
distribution of superantigens profiles identified among emm types, suggesting 
diversity rather than emm type specificity e.g. SAg profile A (speG) only was 
identified in thirteen different emm types; profile B (speB,C,F,G,H,J) was observed 
eight emm types (Table 5-3).  The SAg profiles illustrated in Table 5-3 and those 
seen in another study [37] show that isolates belonging to the same emm type do not 
necessarily have similar SAg profiles.  The study by Rivera identified at least a 
single toxin gene difference between similar emm types [37].  However, these 
finding contradicts previous studies which report restriction of certain SAg profiles 
to emm types [30, 42].  The study by Schmitz observed certain emm types were 
characterised by dominance of 1 or 2 toxin genes profiles e.g. 40 out of 72 emm1 
investigated contained speA, speB, speF, speG, speJ and smeZ [42].  However, other 
emm1 with variable SAg profiles were present [42].  Interestingly 27 out of 29 emm1 
reported by Commons featured speA, speG, speJ and smeZ [30].  These SAg were 
also harboured in emm4 [30]. 
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Individual emm types such as; emm1, emm4, emm12, emm28, and emm75, are said to 
feature unique SAg genes [30, 35, 87].  In this study, emm1 featured in three SAg 
profiles, A, E and F, which collectively featured all eight genes investigated, (Table 
5-3).  However the SAg gene identified in emm1 are not in accordance with a study 
by Descheemaeker which documented presence of speA, speB and speF in emm1 and 
also noticed the absence of speC and ssa, which was also observed in a study by 
Vlamininckx [35, 87].  The absence of speC from emm1 contrasts with a Tunisian 
study which demonstrated presence of this gene in emm1, in line with two more 
studies [30, 37, 48].  Hence, with these results in mind, emm1 in some instances does 
not exclusively lack speC, since results from this study and other studies [30, 37, 48] 
have identified this SAg gene from emm1.  
 
The multiplex PCR in this study was successful in determining the SAg profiles from 
the 98 isolates.  Regardless of the SAg profile identified, there was no close 
relationship with the emm types.  The same applies to the most prevalent 
streptococcal exotoxin gene. 
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Chapter Six: Conclusions 
 
Conclusions 
 
The results of the emm-typing show a greater diversity of emm-typpes among GAS 
isolates from Cape Town than has been reported in developed countries, and the 
proposed 26-valent vaccine would theoretically provide 51.7% coverage. This 
vaccine coverage supports calls for a reconsideration of the M-protein currently 
included in the 26-valent and the 30-valent GAS vaccine.  The coverage observed is 
typical of developing countries where a diversity of emm-types exist, contrary to the 
high vaccine coverage observed in developed countries due to the dominance of only 
a few emm-types.  Based on the data from this study, the dominant M48.1 does not 
featured in the experimental 26-valent GAS vaccines translating into a vaccine 
coverage of 51.7% contrasting up to 85% coverage anticipated from developed 
countries such as the US and Canada.  
 
As an alternative to the sequencing assay, restriction fragment length polymorphism 
(RFLP) assay produced restriction patterns distinct enough to enable differentiation 
of the locally observed emm-types.  The ability of restriction enzymes to produce 
distinguishable restriction patterns of M-proteins makes RFLP a useful assay for 
typing M-protein.  Of the five enzymes recommended by the CDC, double digestion 
with HaeIII and HincII produced distinct restriction patterns that were relatively easy 
to analyse.  Although not commonly used in molecular epidemiology of the M-
protein, RFLP results from this study suggests the effectiveness of this assay in 
determining differences among M-protein, particularly when a large number of 
isolates are involved.  Hence, with regards to some developing countries where 
sequencing can be a challenge, RFLP can be useful in segregating similar M-protein, 
reducing the number of samples for sequencing, particularly when a large sample 
size is involved. 
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Sequence analyses of the conserved region of the M-protein confirm four potential 
vaccine targets conserved among GAS isolates.  Contrary to the type specific 26-
valent and 30-valent GAS vaccine in which a low vaccine coverage is evident in 
Cape Town, three out of the four vaccine targets are harboured in at least two 
conserved regions across all emm-types examined, regardless of the emm- type.  The 
results from this study as well as reports from other studies across the globe have 
identified similar vaccine targets in GAS isolates.  A vaccine targeting the four 
conserved regions has a potential to have universal relevance, unlike the M-protein 
based vaccine which has geographical variation in coverage.  
 
The first multiplex PCR utilized to detect superantigen genes of GAS, streptococcal 
superantigens in South Africa, show no connection between SAg and M-protein 
types.  Among the eight genes investigated, restriction profiles identified show no 
mutual relation with the M-protein types. Although superantigens are believed to 
largely contribute to the global surge of streptococcal diseases, no individual 
superantigen among those investigated in this study correlate with pharyngeal 
infection. 
The thesis had a few limitations.  The number of participants in each of the 
symptomatic and asymptomatic groups was small, thus not allowing for meaningful 
comparisons between the groups.  The dearth of molecular data from South and sub-
Saharan Africa also made it difficult to contextualise our results, especially against 
those data from developed countries where the majority of vaccine development is 
underway. 
In summary, to the best of author’s knowledge, this is the first study describing the 
molecular epidemiology of GAS in South Africa.  The M-protein sequence typing as 
well RFLP proved useful in identifying GAS. Sequence typing remains the gold 
standard for molecular epidemiology studies of GAS.  Both sequencing and RFLP 
show a diversity of M-protein circulating in Cape Town, calling for new vaccine 
formulation that will include prominent M-protein from Cape Town.  Interestingly, 
sequence analysis of the conserved region of the M-protein identified potential 
vaccine targets conserved among GAS strains, injecting some hope of a much needed 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
88 | P a g e  
 
GAS vaccine that is not M-protein specific and can be used regardless of the global 
distribution of the M-protein. 
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Appendix A 
 
 
50X stock TAE buffer  
242 g         Tris base 
27.1 ml     glacial acetic acid 
37.2 g         Na2EDTA 2H2O 
pH 8.5 
 
Prepare to 1 litre with distilled water 
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Appendix B 
 
Molecular markers used in agarose gel electrophoresis 
 
 
 
 
 
  
HyperLadder I HyperLadder IV 
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Appendix C 
DdeI digests 
Restriction pattern of representative emm types following digestion with DdeI, 
separated on a 3% agarose gel electrophoresis for 6 hours  
 
     1          2          3          4         5          6         7         8          9        10        11        12 
 
 
 
 
 
 
 
 
 
 
 
     
Lane 1 and 12 are molecular markers (HyperLadder IV, Appendix A).  Lane 
2 emm12,  Lane 3 emm28,  Lane 4  emm94,  Lane 5 emm89, Lane 6 emm94, 
Lane 7 emm94, Lane 8  emm6.4, Lane 9 emm12, Lane 10 emm4 , Lane 11  
emm89 
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    1   2    3   4    5    6    7    8    9  10  11 12  13  14  15 16  17  18  19  20  21  22  23  
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 16 are molecular markers (HyperLadder IV, Appendix A).  Lane 2 
emm12, Lane 3 st2002.2, Lane 4 emm116.1,  Lane 5 emm28, Lane 6 emm87, Lane 7 
emm94, Lane 8 emm1, Lane 9 emm89, Lane 10 emm94, Lane 11 emm53, Lane 12 
emm94 , Lane 13 emm6.4, Lane 14 emm12, Lane 15 emm4, Lane 17 emm89, Lane 18 
emm89, Lane 19 emm53, Lane 20 emm116, Lane 21 emm 4, Lane 22 emm12, Lane 
23 emm89   
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          1         2        3          4           5       6        7         8          9       10       11       12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 12 are molecular markers (HyperLadder IV, Appendix A).  Lane 2 
emm8, Lane 3 emm118, Lane 4 emm58, Lane 5 emm4,  Lane 6 emm82, Lane 7 
emm77, Lane 8 emm49, Lane 9, Lane 10 emm9, Lane 11 emm116  
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    1     2      3     5    6     7      8      9    10  11   12    13   14  15   16    17   18   19  20   21   22   23   
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 23 are molecular markers (HyperLadder IV, Appendix A).  Lane 2 
emm89, Lane 3 emm87, Lane 4 emm44, Lane 5 emm22, Lane 6 emm80, Lane 7 
emm33, Lane 8 emm48.1, Lane 9 emm6.4, Lane 10 emm48.1, Lane 11 emm77, Lane 
12 emm48.1, Lane 13 emm92, Lane 14, Lane 15 emm116.1, Lane 16 emm1, Lane 17 
emm8, Lane 18 emm58.2, Lane 19 emm82, Lane 20 emm77, Lane 21 emm53 
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MboI digests 
Restriction pattern of representative emm types following digestion with MboI, 
separated on a 3% agarose gel electrophoresis for 6 hours  
 
       1          2         3        4         5         6          7        8         9        10        11       12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 12 are molecular markers (HyperLadder IV, Appendix A).  Lane 1 and 
20 are molecular markers (HyperLadder IV, Appendix A).  Lane 2 emm12,  Lane 3 
emm28,  Lane 4  emm94,  Lane 5 emm89, Lane 6 emm94, Lane 7 emm94, Lane 8  
emm6.4, Lane 9 emm12, Lane 10 emm4 , Lane 11  emm89 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
116 | P a g e  
 
 
          1    2     3    4     5    6    7     8    9    10  11  12 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 12 are molecular markers 
(HyperLadder IV, Appendix A).  Lane 
2 emm8, Lane 3 emm118, Lane 4 
emm58, Lane 5 emm4,  Lane 6 emm82, 
Lane 7 emm77, Lane 8 emm49, Lane 9, 
Lane 10 emm9, Lane 11 emm116  
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
117 | P a g e  
 
 
 
 
    1      2       3      4       5       6      7      8     9      10    11    12    13     14     15  16   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 16 are molecular markers (HyperLadder IV, Appendix A).  Lane 2 
emm12, Lane 3 st2002.2, Lane 4 emm116, Lane 5 emm28, Lane 6 emm97, Lane 7 
emm94, Lane 8 emm1, Lane 9 emm89, Lane 10 emm94, Lane 11 emm22, Lane 12 
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   1         2       3        4        5       6        7        8        9       10      11      12      13      14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 14 are molecular markers (HyperLadder IV, Appendix A).  Lane 2 
emm53, Lane 3 emm94, Lane 4 emm6.4, Lane 5 emm12, Lane 6 emm4, Lane 7 
emm89, Lane 8 emm89, Lane 9 emm94, Lane 10 emm116, Lane 11 emm4, Lane 12 
emm12, Lane 13 emm89   
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  1    2     3    4    5    6    7     8    9   10  11   12  13  14  15  16   17  18  19   20   21   
22   
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 22 are molecular markers (HyperLadder IV, Appendix A).  Lane 2 
emm89, Lane 3 emm87, Lane 4 emm44, Lane 5 emm22, Lane 6 emm80, Lane 7 
emm33, Lane 8 emm48.1, Lane 9 emm6.4, Lane 10 emm48.1, Lane 11 emm77, Lane 
12 emm48.1, Lane 13 emm92, Lane 14, Lane 15 emm116.1, Lane 16 emm1, Lane 17 
emm8, Lane 18 emm58.2, Lane 19 emm82, Lane 20 emm77, Lane 21 emm53 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
120 | P a g e  
 
 
 
 
 
SacI digests 
Restriction pattern of representative emm types following digestion with SacI, 
separated on a 3% agarose gel electrophoresis for 6 hours  
 
 1     2     3    4     5     6     7    8     9    10   11   12   
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 12 are molecular markers 
(HyperLadder IV, Appendix A).  
Lane 2 emm12,  Lane 3 emm28,  Lane 
4  emm94,  Lane 5 emm89, Lane 6 
emm94, Lane 7 emm94, Lane 8  
emm6.4, Lane 9 emm12, Lane 10 
emm4 , Lane 11  emm89 
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HaeIII and HincII digests  
Restriction pattern of representative emm types following digestion with HaeIII and 
HincII, separated on a 3% agarose gel electrophoresis for 6 hours  
 
    1    2    3     4    5    6    7    8     9   10  11  12 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 12 are molecular markers 
(HyperLadder IV, Appendix A).  Lane 
2 emm12, Lane 3 emm28, Lane 4  
emm94, Lane 5 emm89, Lane 6 emm94, 
Lane 7 emm94, Lane 8  emm6.4, Lane 
9 emm12, Lane 10 emm4 , Lane 11  
emm89 
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    1    2     3    4    5     6    7    8     9   10   11  12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 12 are molecular markers 
(HyperLadder IV, Appendix A).  Lane 2 
emm8, Lane 3 emm118, Lane 4 emm58, 
Lane 5 emm4,  Lane 6 emm82, Lane 7 
emm77, Lane 8 emm49, Lane 9, Lane 10 
emm9, Lane 11 emm116  
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    1   2    3    4     5    6   7    8     9   10  11 12  13   14  15  16  17  18  19   20  21  22   
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 22 are molecular markers (HyperLadder IV, Appendix A).  Lane 2 
emm89, Lane 3 emm87, Lane 4 emm44, Lane 5 emm22, Lane 6 emm80, Lane 7 
emm33, Lane 8 emm48.1, Lane 9 emm6.4, Lane 10 emm48.1, Lane 11 emm77, Lane 
12 emm48.1, Lane 13 emm92, Lane 14, Lane 15 emm1, Lane 16 emm116.1, Lane 17 
emm8, Lane 18 emm58.2, Lane 19 emm82, Lane 20 i, Lane 21 emm53.  
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   1    2     3     4     5    6     7    8     9   10   11   12   13  14   15  16    17  18  19   20    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 20 are molecular markers (HyperLadder IV, Appendix A).  Lane 2 
emm12, Lane 3 st2002.2, Lane 4 emm116, Lane 5 emm28, Lane 6 emm87, Lane 7 
emm94, Lane 8 emm1, Lane 9 emm44, Lane 10 emm89, Lane 11 emm94, Lane 12 
emm22, Lane 13 emm94, Lane 14 emm6.4, Lane 15 emm12, Lane 16 emm4, Lane 17 
emm89, Lane 18 emm80 and Lane 19 emm89.   
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   1    2    3     4     5    6    7    8     9    10   11  12  13  14  15   16   17  18  19   20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 and 20 are molecular markers (HyperLadder IV, Appendix A).  
Lane 2 emm12, Lane 3 st2002.2, Lane 4 emm116, Lane 5 emm28, Lane 6 
emm87, Lane 7 emm94, Lane 8 emm1, Lane 9 emm44, Lane 10 emm89, 
Lane 11 emm94, Lane 12 emm22, Lane 13 emm94, Lane 14 emm6.4, Lane 
15 emm12, Lane 16 emm4, Lane 17 emm89, Lane 18 emm80 and Lane 19 
emm89.  
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Appendix D 
Amino acid (single letter and representative codons) 
 
Amino acid Symbol Codons 
Isoleucine    I ATT, ATC, ATA 
Leucine    L CTT, CTC, CTA, CTG, TTA, TTG 
Valine  V GTT, GTC, GTA, GTG 
Phenylalanine    F TTT, TTC 
Methionine M ATG 
Cysteine  C TGT, TGC 
Alanine        A GCT, GCC, GCA, GCG  
Glycine    G GGT, GGC, GGA, GGG  
Proline        P CCT, CCC, CCA, CCG 
Threonine    T ACT, ACC, ACA, ACG 
Serine         S TCT, TCC, TCA, TCG, AGT, AGC 
Tyrosine    Y TAT, TAC 
Tryptophan    W TGG 
Glutamine    Q CAA, CAG 
Asparagine    N AAT, AAC 
Histidine  H CAT, CAC 
Glutamic acid    E GAA, GAG 
Aspartic acid   D GAT, GAC 
Lysine         K AAA, AAG 
Arginine    R CGT, CGC, CGA, CGG, AGA, AGG 
Stop codons  Stop  TAA 
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Alignment of sequences generated from the C-region of the M-
protein 
Sequence alignment of C1-repreat 
Name  Sites    
emm89 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKDLEAEHQKLKE 
emm118 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKDLEAEHQKLKE 
emm15  QLETEKQISEASRKSLSRDLEASRAAKKDLEAEHQKLKE 
emm82 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKDLEAEHQKLKE 
emm118 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKDLEAEHQKLKE 
emm89 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKDLEAEHQKLKE 
emm58 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKDLEAEHQKLKE 
emm8 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKELEAEHQKLKE 
emm44 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKELEAEHQKLKE 
emm77 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKELEAEHQKLKE 
emm44 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKELEAEHQKLKE 
emm8 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKELEAEHQKLKE 
emm22 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASRAAKKGLEAEHQKLKE 
emm22 QKQQ QLETEKQISEASRKSLSRDLEASRAAKKKVEADLAALNA 
emm82 KDTLAEKAK KLEEDKQISDASRKSLSRDLEASRAAKKELEAKXQKLET 
emm49 KAK KLEEDKQISDASRKSLSRDLEASRAAKKELEANHQKLET 
emm94 EKDTLAEKAK KLEEDKQISDASRKSLSRDLEASRAAKKELEAKHQKLET 
emm4 AK KLEEDKQISDASRKSLSRDLEASRAAKKELEANHQKLET 
emm94 EKDTLAEKAK KLEEDKQISDASRKSLSRDLEASRAAKKELEAKHQKLET 
emm48 EKDTLAEKAK KLEEDKQISDASRKSLSRDLEASRAAKKELEANHQKLET 
emm48 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASREAKKKVEADLAALTA 
emm49 RYQEQLQKQQ QLETEKQISEASRKSLSRDLEASREAKKKVEADLAALTA 
emm92 RYQEQLQKQQ QLEKEKQISEASRKSLSRDLEASRAAKKDLEAEHQKLKE 
emm92 RYQEQLQKQQ QLEKEKQISEASRKSLSRDLEASRAAKKDLEAEHQKLKE 
emm1 EKEQLTIEKA KLEEEKQISDASRQSLRRDLDASREAKKQVEKDLANLTA 
emm1 EKA KLEEEKQISDASRQSLRRDLDASREAKKQVEKDLANLTA 
emm116 ERKEKEAEQK KLKEEKQISDASRQGLRRDLDASREAKKQVEKDLANLTT 
emm116 ERKEKEAEQK KLKEEKQISDASRQGLRRDLDASREAKKQVEKDLANLTT 
emm116 ERKEKEAEQK KLKEEKQISDASRQGLRRDLDASREAKKQVEKDLANLTT 
emm80 DLANLTAELG KVKEEKQISDASRQGLRRDLDASREAKKQVEKDLANLTA 
emm53 DLANLTAELD KVKEEKQISDASRQGLRRDLDASREAKKQVEKGLANLTA 
emm53 DLANLTAELD KVKEEKQISDASRQGLRRDLDASREAKKQVEKGLANLTA 
emm22 Q KLAKDKQISDASRQGLSRDLEASRAAKKELEAKHQKLEA 
emm4 KHQKLEAENK KLTEANQVSEASRKGLSNDLEASRAAKKELEAKHQKLEA 
emm4 KHQKLEAENK KLTEANQVSEASRKGLSNDLEASRAAKKELEAKHQKLEA 
emm48 KHQKLEAENK KLTEANQVSEASRKGLSNDLEASRAAKKELEAKHQKLEA 
emm4 KHQKLEAENK KLTEANQVSEASRKGLSNDLEASRAAKKELEAKHQKLEA 
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Sequence alignment of C2-repreat 
Name  Sites  
emm49 KELEANHQKL ETEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm4 KELEANHQKL ETEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm48 KELEANHQKL ETEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm48 KKVEADLAAL TAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm49 KKVEADLAAL TAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm94 KELEAKHQKL ETEHQKLKEDKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm94 KELEAKHQKL ETEHQKLKEDKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm89 EASRAAKKDL EAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm118 EASRAAKKDL EAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm14 EASRAAKKEL EAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm89 EASRAAKKDL EAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm44 EASRAAKKEL EAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm8 EASRAAKKEL EAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm15 EASRAAKKDL EAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm22 EASRAAKKGL EAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAA LNAEHQKLKE 
emm92 EASRAAKKDL EAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm92 EASRAAKKDL EAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm58 EASRAAKKDL EAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAA LNAEHQKLKE 
emm8 EASRAAKKEL EAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm118 KQVEKDLANL TTELDKVKEEKQISDASRQGLRRDLDASREAKKKVEADLAA LTAEHQKLKE 
emm116 KQVEKDLANL TTELDKVKEEKQISDASRQGLRRDLDASREAKKKVEADLAA LTAEHQKLKE 
emm82 EASRAAKKDL EAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAT LNAEHQKLKE 
emm82 KELEAKXQKL ETEXQKLKEDKQISDASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm118 EASRAAKKDL EAEHQKLKEEKQISXASRQGLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm80 NEKEAERKEK EAEQKKLKEEKQISDASRQGLRRDLDASREAKKQVEKDLAN LTAELGKVKE 
emm53 NGALRYINEK EAEQKKLKEEKQISDASRQGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
emm53 RYINEK EAEQKKLKEEKQISDASRQGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
emm1 KQVEKDLANL TAELDKVKEDKQISDASRQGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
emm1 KQVEKDLANL TAELDKVKEDKQISDASRQGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
emm9 REIDKRYQEQ LQKQQQLETEKQISEASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm9 REIDKRYQEQ LQKQQQLETEKQISEASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm9 REIDKRYQEQ LQKQQQLETEKQISEASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm9 REIDKRYQEQ LQKQQQLETEKQISEASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm9 REIDKRYQEQ LQKQQQLETEKQISEASRKSLSRDLEASREAKKKVEADLAA LTAEHQKLKE 
emm22 REIDKRYQEQ LQKQQQLETEKQISEASRKSLSRDLEASRAAKKKVEADLAA LNAEHQKLKE 
emm22 REIDKRYQEQ LQKQQQLETEKQISEASRKSLSRDLEASRAAKKKVEADLAA LNAEHQKLKE 
emm80 NEKEAERKEK EAEQKKLKEEKQISDASRQGLRRDLDASREAKXQVEKDLAN LTAELGKVKE 
emm116 KQVEKDLANL TTELDKVKEEKQXSDASRQGLRRDLDASREAKKKVEADLAA LTAEHQKLKE 
emm12 EAVRKAKAQV EAALKQLEEQNKISEASRKGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
emm12 EAVRKAKAQV EAALKQLEEQNKISEASRKGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
emm3 EAVRQAKAQV EAALKQLEEQNRISEASRKGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
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emm28 REIDKRYQEQ LQKQQQLETEKQISEASRKSLSRDLEASRAAKKDLEAEHQK LKEEKQISDA 
emm28 REIDKRYQEQ LQKQQQLETEKQISEASRKSLSRDLEASRAAKKDLEAEHQK LKEEKQISDA 
emm4 KKHQQEQQQL EAEKQKLAKDKQISDASRQGLSRDLEASRAAKKELEAKHQK LEAENKKLTE 
emm4 KKHQQEQQQL EAEKQKLAKDKQISDASRQGLSRDLEASRAAKKELEAKHQK LEAENKKLTE 
emm48 KKHQQEQQQL EAEKQKLAKDKQISDASRQGLSRDLEASRAAKKELEAKHQK LEAENKKLTE 
emm6 QKSKQDIGAL KQELAKKDEGNKVSEASRKGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
emm6 QKSKQDIGAL KQELAKKDEGNKVSEASRKGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
emm6 QKSKQDIGAL KQELAKKDEGNKVSEASRKGLRRDLDASREAKKQVEKDLAN LTAELDKVKE 
emm2 REVEKRYQEQ LQKQQQLEKEKQISEASRKSLSRDLEASRAAKKDLEAEHQK LKEEKQISEA 
emm2 REVEKRYQEQ LQKQQQLEKEKQISEASRKSLSRDLEASRAAKKDLEAEHQK LKEEKQISEA 
emm48 NKLTTEKDTL AEKAKKLEEDKQISDASRKSLSRDLEASRAAKKELEANHQK LETEHQKLKE 
st2002 QEQQQKQQQL EAENQKLTEANKVSEASRKGLSNDLEASRAAKKELEAKHQK LEADHQALEA 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
130 | P a g e  
 
 
Sequence alignment of C3-repreat 
Name  Sites  
emm2 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm2 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm49 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm11
6 
KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm8 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm9 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm89 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm11
8 
KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm17 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm44 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm94 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm92 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm9 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm11
6 
KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm9 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm9 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm49 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm11
8 
KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm94 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm92 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm89 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm48 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm44 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
S 
emm9 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm8 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm22 KKKVEADLA
A 
LNAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm22 KKKVEADLA
A 
LNAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm58 KKKVEADLA
A 
LNAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm22 KKKVEADLA
A 
LNAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm28 LEASRAAKK
D 
LEAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm77 LEASRAAKK
E 
LEAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm28 LEASRAAKK
D 
LEAEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm4 KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGXSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm11
6 
KKKVEADLA
A 
LTAEHQKLKEEKQISDASRQGXSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
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emm48 KKELEANHQ
K 
LETEHQKLKEEKQISDASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm2 LEASRAAKK
D 
LEAEHQKLKEEKQISEASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm2 LEASRAAKK
D 
LEAEHQKLKEEKQISEASRQGLSRDLEASREAKKKVEADLAEANSKL
QAL 
E 
emm22 KKKVEADLA
A 
LNAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm82 KKKVEADLA
T 
LNAEHQKLKEEKQISDASRKSLSRDLEASREAKKKVEADLAEANSKL
QAL 
EKLNKELEE
G 
emm80 KKQVEKDLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSKL
AAL 
EKLNKELEE
S 
emm53 KKQVEKGLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSKL
AAL 
EKLNKELEE
S 
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emm6 KKQVEKDLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSK
LAAL 
EKLNKELEE
S 
emm1 KKQVEKDLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSK
LAAL 
EKLNKELXE
S 
emm12 KKQVEKDLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSK
LAAL 
EKLNKELEE
S 
emm1 KKQVEKDLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSK
LAAL 
EKLNKELEE
S 
emm6 KKQVEKDLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSK
LAAL 
EKLNKELEE
S 
emm12 KKQVEKDLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSK
LAAL 
EKLNKELEE
S 
emm6 KKQVEKDLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSK
LAAL 
EKLNKELGR
K 
emm53 KKQVEKGLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSK
LAAL 
EKLNKELEE
S 
emm3 KKQVEKDLA
N 
LTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSK
LAAL 
EKLNKELEE
S 
emm1 KKQVEKDLA
N 
LTAELDKVKEDKQISDASRQGLRRDLDASREAKKQVEKDLANLTAE
LDKV 
KEEKQISDA
S 
emm80 KXQVEKDLA
N 
LTAELGKVKEEKQISDASRRGLRRDLDASREAKKQVEKDLANLTAE
LDKV 
KEEKQISDA
S 
emm4 LEASRAAKK
E 
LEAKHQKLEADYQVSETSRKGLSRDLEASREANKKVTSELTQAKAQ
LSAL 
EESKKLSEK
E 
emm4 LEASRAAKK
E 
LEAKHQKLEADYQVSETSRKGLSRDLEASREANKKVTSELTQAKAQ
LSAL 
EESKKLSEK
E 
emm48.
1 
LEASRAAKK
E 
LEAKHQKLEADYQVSETSRKGLSRDLEASREANKKVTSELTQAKAQ
LSAL 
EESKKLSEK
E 
emm4 LEASRAAKK
E 
LEAKHQKLEADYQVSETSRKGLSRDLEASREANKKVTSELTQAKAQ
LSAL 
EESKKLSEK
E 
st2002 HQKLEADHQ
A 
LEAKHQKLEADHQVSETSRKGLSRDLEASREANKKVTSELTQAKAQ
LSVL 
EESKKLSEK
E 
emm2 LEASRAAKK
E 
LEAKHQKLEADYQVXETSRKGLSRDLEASREANKKVTSELTQAKAQ
LSAL 
EESKKLSEK
E 
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Appendix E 
Basic Alignment Search Tool (BLAST) results of streptococcal 
superantigens 
 
SpeA 
> gb|CP000017.1|  Streptococcus pyogenes MGAS5005, complete genome 
Length=1838554 
 
 Features in this part of subject sequence: 
   enterotoxin 
 
 Score =  385 bits (208),  Expect = 6e-107 
 Identities = 212/214 (99%), Gaps = 1/214 (0%) 
 Strand=Plus/Minus 
 
Query  6       ATATC-AATGATAGGCTTTGGATACCATCGATTGATACTTTAACGACTATCTTTTTAGGA  
64 
               ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  984819  ATATCAAATGATAGGCTTTGGATACCATCGATTGATACTTTAACGACTATCTTTTTAGGA  
984760 
 
Query  65      ATTTCTAAATGATTCCCTTCATGATTTGTTACCCCTCCGTAGATACATGCACTCCTTTCT  
124 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  984759  ATTTCTAAATGATTCCCTTCATGATTTGTTACCCCTCCGTAGATACATGCACTCCTTTCT  
984700 
 
Query  125     GCATTTTCACATAAATAACAGAGATGGTAATATTCTACACTATAAATATCAACGTTTTTA  
184 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  984699  GCATTTTCACATAAATAACAGAGATGGTAATATTCTACACTATAAATATCAACGTTTTTA  
984640 
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Query  185     TCCTTAAATAAAGTTGCCATCTCTTGGTTYTTAA  218 
               ||||||||||||||||||||||||||||| |||| 
Sbjct  984639  TCCTTAAATAAAGTTGCCATCTCTTGGTTCTTAA  984606 
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SpeB 
> gb|AE004092.1|  Streptococcus pyogenes M1 GAS, complete genome 
Length=1852441 
 
 Features in this part of subject sequence: 
   pyrogenic exotoxin B 
 
 Score = 1633 bits (884),  Expect = 0.0 
 Identities = 888/890 (99%), Gaps = 1/890 (0%) 
 Strand=Plus/Minus 
 
Query  37       ACGAAGCGCAGAAGATATTAASCTTGACAAAGTTAACTTAGGTGGAGAACTTTCTGGCTC  
96 
                ||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||| 
Sbjct  1699690  ACGAAGCGCAGAAGATATTAAGCTTGACAAAGTTAACTTAGGTGGAGAACTTTCTGGCTC  
1699631 
 
Query  97       TAATATGTATGTTTACAATATTTCTACTGGAGGATTTGTTATCGTTTCAGGAGATAAACG  
156 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1699630  TAATATGTATGTTTACAATATTTCTACTGGAGGATTTGTTATCGTTTCAGGAGATAAACG  
1699571 
 
Query  157      TTCTCCAGAAATTCTAGGATACTCTACCAGCGGATCATTTGACGCTAACGGTAAAGAAAA  
216 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1699570  TTCTCCAGAAATTCTAGGATACTCTACCAGCGGATCATTTGACGCTAACGGTAAAGAAAA  
1699511 
 
Query  217      CATTGCTTCCTTCATGGAAAGTTATGTCGAACAAATCAAAGAAAACAAAAAATTAGACAC  
276 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1699510  CATTGCTTCCTTCATGGAAAGTTATGTCGAACAAATCAAAGAAAACAAAAAATTAGACAC  
1699451 
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Query  277      TACTTATGCTGGTACCGCTGAGATTAAACAACCAGTTGTTAAATCTCTCCTTGATTCAAA  
336 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1699450  TACTTATGCTGGTACCGCTGAGATTAAACAACCAGTTGTTAAATCTCTCCTTGATTCAAA  
1699391 
 
Query  337      AGGCATTCATTACAATCAAGGTAACCCTTACAACCTATTGACACCTGTTATTGAAAAAGT  
396 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1699390  AGGCATTCATTACAATCAAGGTAACCCTTACAACCTATTGACACCTGTTATTGAAAAAGT  
1699331 
 
Query  397      AAAACCAGGTGAACAATCTTTTGTAGGTCAACATGCAGCTACAGGATGTGTTGCTACTGC  
456 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1699330  AAAACCAGGTGAACAATCTTTTGTAGGTCAACATGCAGCTACAGGATGTGTTGCTACTGC  
1699271 
 
Query  457      AACTGCTCAAATTATGAAATATCATAATTACCCTAACAAAGGGTTGAAAGACTACACTTA  
516 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1699270  AACTGCTCAAATTATGAAATATCATAATTACCCTAACAAAGGGTTGAAAGACTACACTTA  
1699211 
 
Query  517      CACACTAAGCTCAAATAACCCATATTTCAACCATCCTAAGAACTTGTTTGCAGCTATCTC  
576 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1699210  CACACTAAGCTCAAATAACCCATATTTCAACCATCCTAAGAACTTGTTTGCAGCTATCTC  
1699151 
 
Query  577      TACTAGACAATACAACTGGAACAACATCTTACCTACTTATAGCGGAAGAGAATCTAACGT  
636 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1699150  TACTAGACAATACAACTGGAACAACATCTTACCTACTTATAGCGGAAGAGAATCTAACGT  
1699091 
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SpeC 
 
> gb|AE004092.1|  Streptococcus pyogenes M1 GAS, complete genome 
Length=1852441 
 
 Features in this part of subject sequence: 
   pyrogenic exotoxin C precursor, phage associated 
 
 Score =  985 bits (533),  Expect = 0.0 
 Identities = 544/550 (99%), Gaps = 3/550 (1%) 
 Strand=Plus/Minus 
 
Query  9       TCT-AGAAGAGACATTTCGAATGTTAAAAGTGATTTACTTTATGCATACACTATAACTCC  
67 
                       ||| |||| 
||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  569204  TCTAAGAA-AGACATTTCGAATGTTAAAAGTGATTTACTTTATGCATACACTATAACTCC  
569146 
 
Query  68      TTATGATTATAAAAATTGCAGGGTAAATTTTTCAACGACACACACATTAAACATTGATAC  
127 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  569145  TTATGATTATAAAAATTGCAGGGTAAATTTTTCAACGACACACACATTAAACATTGATAC  
569086 
 
Query  128     TCAAAAATATAGAGGGAAAGACTATTATATTAGTTCCGAAATGTCTTATGAGGCCTCTCA  
187 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  569085  TCAAAAATATAGAGGGAAAGACTATTATATTAGTTCCGAAATGTCTTATGAGGCCTCTCA  
569026 
 
Query  188     AAAATTTAAACGAGATGATCATGTAGATGTTTTTGGATTATTTTATATTCTTAATTCTCA  
247 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  569025  AAAATTTAAACGAGATGATCATGTAGATGTTTTTGGATTATTTTATATTCTTAATTCTCA  
568966 
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Query  248     CACCGGTGAGTACATCTATGGAGGAATTACGCCTGCTCAAAATAATAAAGTAAATCATAA  
307 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  568965  CACCGGTGAGTACATCTATGGAGGAATTACGCCTGCTCAAAATAATAAAGTAAATCATAA  
568906 
 
Query  308     ATTATTGGGAAATCTATTTATTTCGGGAGAATCTCAACAGAACTTAAATAACAAAATTAT  
367 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  568905  ATTATTGGGAAATCTATTTATTTCGGGAGAATCTCAACAGAACTTAAATAACAAAATTAT  
568846 
 
Query  368     TCTAGAAAAAGATATCGTAACTTTCCAGGAAATTGACTTTAAAATCAGAAAATACCTTAT  
427 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  568845  TCTAGAAAAAGATATCGTAACTTTCCAGGAAATTGACTTTAAAATCAGAAAATACCTTAT  
568786 
 
Query  428     GGATAATTATAAAATTTATGACGCTACTTCTCCTTATGTAAGCGGCAGAATCGAAATTGG  
487 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  568785  GGATAATTATAAAATTTATGACGCTACTTCTCCTTATGTAAGCGGCAGAATCGAAATTGG  
568726 
 
Query  488     CACAAAAGATGGGAAACATGAGCAAATAGACTTTATTTGACTCACCAAATGAAGGGACTA  
547 
               ||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||| 
Sbjct  568725  CACAAAAGATGGGAAACATGAGCAAATAGACTT-ATTTGACTCACCAAATGAAGGGACTA  
568667 
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SpeF 
 
 
> gb|AE004092.1|  Streptococcus pyogenes M1 GAS, complete genome 
Length=1852441 
 
 Features in this part of subject sequence: 
   mitogenic factor 
 
 Score = 1354 bits (733),  Expect = 0.0 
 Identities = 743/747 (99%), Gaps = 3/747 (0%) 
 Strand=Plus/Minus 
 
Query  10       GCTAGTAAAATTTTTC-ATGGTAGCTCTTGTATCAGCCACAATGGCTGTAACAACAGTCA  
68 
                |||||||||| ||||| ||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702652  GCTAGTAAAA-TTTTCAATGGTAGCTCTTGTATCAGCCACAATGGCTGTAACAACAGTCA  
1702594 
 
Query  69       CACTTGAAAATACTGCACTGGCACGACAAACACAGGTCTCAAATGATGTTGTTCTAAATG  
128 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702593  CACTTGAAAATACTGCACTGGCACGACAAACACAGGTCTCAAATGATGTTGTTCTAAATG  
1702534 
 
Query  129      ATGGCGCAAGCAAGTACCTAAACGAAGCATTAGCTTGGACATTCAATGACAGTCCCAACT  
188 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702533  ATGGCGCAAGCAAGTACCTAAACGAAGCATTAGCTTGGACATTCAATGACAGTCCCAACT  
1702474 
 
Query  189      ATTACAAAACCTTAGGTACTAGTCAGATCACTCCAGCACTCTTTCCTAAAGCAGGAGATA  
248 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702473  ATTACAAAACCTTAGGTACTAGTCAGATCACTCCAGCACTCTTTCCTAAAGCAGGAGATA  
1702414 
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Query  249      TTCTCTATAGCAAATTAGATGAGTTAGGAAGGACGCGTACTGCTAGAGGTACATTGACTT  
308 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702413  TTCTCTATAGCAAATTAGATGAGTTAGGAAGGACGCGTACTGCTAGAGGTACATTGACTT  
1702354 
 
Query  309      ATGCCAATGTTGAAGGTAGCTACGGTGTTAGACAATCTTTCGGTAAAAATCAAAACCCCG  
368 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702353  ATGCCAATGTTGAAGGTAGCTACGGTGTTAGACAATCTTTCGGTAAAAATCAAAACCCCG  
1702294 
 
Query  369      CAGGCTGGACTGGAAACCCTAATCATGTCAAATATAAAATTGAATGGTTAAATGGTCTAT  
428 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702293  CAGGCTGGACTGGAAACCCTAATCATGTCAAATATAAAATTGAATGGTTAAATGGTCTAT  
1702234 
 
Query  429      CTTATGTCGGAGATTTCTGGAATAGAAGTCATCTCATTGCAGATAGTCTCGGTGGAGATG  
488 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702233  CTTATGTCGGAGATTTCTGGAATAGAAGTCATCTCATTGCAGATAGTCTCGGTGGAGATG  
1702174 
 
Query  489      CACTCAGAGTCAATGCCGTTACAGGGACACGTACCCAAAATGTAGGAGGTCGTGACCAAA  
548 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702173  CACTCAGAGTCAATGCCGTTACAGGGACACGTACCCAAAATGTAGGAGGTCGTGACCAAA  
1702114 
 
Query  549      AAGGCGGCATGCGCTATACCGAACAAAGAGCTCAAGAATGGTTAGAAGCAAATCGTGATG  
608 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1702113  AAGGCGGCATGCGCTATACCGAACAAAGAGCTCAAGAATGGTTAGAAGCAAATCGTGATG  
1702054 
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
141 | P a g e  
 
SpeG 
 
> gb|AE009949.1|  Streptococcus pyogenes MGAS8232, complete genome 
Length=1895017 
 
 Features in this part of subject sequence: 
   exotoxin G precursor 
 
 Score =  206 bits (111),  Expect = 3e-53 
 Identities = 111/111 (100%), Gaps = 0/111 (0%) 
 Strand=Plus/Plus 
 
Query  9       ACAGTTTACTTTACAGGAATTTGATTTTAAAATAAGAAAATTTCTAATGGAAAAATACAA  
68 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  185048  ACAGTTTACTTTACAGGAATTTGATTTTAAAATAAGAAAATTTCTAATGGAAAAATACAA  
185107 
 
Query  69      TATCTATGATTCGGAATCGCGTTATACATCGGGGAGCCTTTTCCTTGCTAC  119 
               ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  185108  TATCTATGATTCGGAATCGCGTTATACATCGGGGAGCCTTTTCCTTGCTAC  185158 
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SpeH 
> emb|AM295007.1|  Streptococcus pyogenes Manfredo complete genome 
Length=1841271 
 
 Features in this part of subject sequence: 
   streptococcal exotoxin H precursor 
 
 Score =  697 bits (377),  Expect = 0.0 
 Identities = 381/383 (99%), Gaps = 0/383 (0%) 
 Strand=Plus/Minus 
 
Query  5        GAAGTAGATATTTATGCTCTATCTGCACAAGAGGTTTGTGAATGTCCAGGGAAAAGGTAT  
64 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1030920  GAAGTAGATATTTATGCTCTATCTGCACAAGAGGTTTGTGAATGTCCAGGGAAAAGGTAT  
1030861 
 
Query  65       GAAGCGTTTGGTGGAATTACATTAACTAATTCAGAAAAAAAAGAAATTAAAGTTCCTGTA  
124 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1030860  GAAGCGTTTGGTGGAATTACATTAACTAATTCAGAAAAAAAAGAAATTAAAGTTCCTGTA  
1030801 
 
Query  125      AACGTGTGGGATAAAAGTAAACAACAGCCGCCTATGTTTATTACAGTCAATAAACCGAAA  
184 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1030800  AACGTGTGGGATAAAAGTAAACAACAGCCGCCTATGTTTATTACAGTCAATAAACCGAAA  
1030741 
 
Query  185      GTAACCGCTCAGGAAGTGGATATAAAAGTTAGAAAGTTATTGATTAAGAAATACGATATT  
244 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct  1030740  GTAACCGCTCAGGAAGTGGATATAAAAGTTAGAAAGTTATTGATTAAGAAATACGATATC  
1030681 
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Query  245      TATAATAATCGGGAACAAAAATACTCTAAAGGAACTGTTACCTTAGATTTAAATTCAGGT  
304 
                |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1030680  TATAATAACCGGGAACAAAAATACTCTAAAGGAACTGTTACCTTAGATTTAAATTCAGGT  
1030621 
 
Query  305      AAAGATATTGTTTTTGATTTGTATTATTTTGGCAATGGAGACTTTAATAGCATGCTAAAA  
364 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1030620  AAAGATATTGTTTTTGATTTGTATTATTTTGGCAATGGAGACTTTAATAGCATGCTAAAA  
1030561 
 
Query  365      ATATATTCCAATAACGAGAGAAT  387 
                ||||||||||||||||||||||| 
Sbjct  1030560  ATATATTCCAATAACGAGAGAAT  1030538 
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SpeJ 
 
> gb|CP000017.1|  Streptococcus pyogenes MGAS5005, complete genome 
Length=1838554 
 
 Features in this part of subject sequence: 
   exotoxin type J precursor 
 
 Score =  905 bits (490),  Expect = 0.0 
 Identities = 492/493 (99%), Gaps = 0/493 (0%) 
 Strand=Plus/Minus 
 
Query  8       ATTTAAGACGTTAAGCTACAATTAAATTACGCATACGAAATCATACCAGTAGATTATACG  
67 
               ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  362651  ATTAAAGACGTTAAGCTACAATTAAATTACGCATACGAAATCATACCAGTAGATTATACG  
362592 
 
Query  68      AATTGTAATATTGATTACTTGACTACTCATGATTTTTATATTGATATTTCCAGTTATAAA  
127 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  362591  AATTGTAATATTGATTACTTGACTACTCATGATTTTTATATTGATATTTCCAGTTATAAA  
362532 
 
Query  128     AAGAAAAATTTTTCAGTTGATTCTGAGGTCGAGAGCTATATTACAACAAAGTTTACGAAA  
187 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  362531  AAGAAAAATTTTTCAGTTGATTCTGAGGTCGAGAGCTATATTACAACAAAGTTTACGAAA  
362472 
 
Query  188     AATCAAAAAGTAAATATTTTTGGTCTTCCGTACATATTTACTCGTTATGATGTTTATTAT  
247 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  362471  AATCAAAAAGTAAATATTTTTGGTCTTCCGTACATATTTACTCGTTATGATGTTTATTAT  
362412 
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Query  248     ATATATGGTGGGGTTACACCATCAGTAAACAGTAATTCGGAAAATAGTAAAATTGTAGGT  
307 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  362411  ATATATGGTGGGGTTACACCATCAGTAAACAGTAATTCGGAAAATAGTAAAATTGTAGGT  
362352 
 
Query  308     AATTTACTAATAGATGGAGTCCAGCAAAAAACACTAATAAATCCCATAAAAATAGATAAA  
367 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  362351  AATTTACTAATAGATGGAGTCCAGCAAAAAACACTAATAAATCCCATAAAAATAGATAAA  
362292 
 
Query  368     CCTATTTTTACGATTCAAGAATTTGACTTCAAAATCAGACAATATCTTATGCAAACATAC  
427 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  362291  CCTATTTTTACGATTCAAGAATTTGACTTCAAAATCAGACAATATCTTATGCAAACATAC  
362232 
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SmeZ 
 
> gb|AE004092.1|  Streptococcus pyogenes M1 GAS, complete genome 
Length=1852441 
 
 Features in this part of subject sequence: 
   mitogenic exotoxin Z 
 
 Score =  608 bits (329),  Expect = 6e-174 
 Identities = 335/340 (99%), Gaps = 0/340 (0%) 
 Strand=Plus/Plus 
 
Query  8        TATTTTTTCTTTTACTTCAATATTCATTGCAATAATTTCTCGTCCTGKGTTTGGATTAGA  
67 
                ||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||| 
Sbjct  1665203  TATTTTTTCTTTTACTTCAATATTCATTGCAATAATTTCTCGTCCTGTGTTTGGATTAGA  
1665262 
 
Query  68       AGTAGATAATAATTCCCTTCTAAGGAATATCTATAGTACGATTGTATATGAATATTCAGA  
127 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1665263  AGTAGATAATAATTCCCTTCTAAGGAATATCTATAGTACGATTGTATATGAATATTCAGA  
1665322 
 
Query  128      TACAGTAATTGATTTTAAAACCAGTCATAACTTAGTGACTAARAAACTTGATGTTAGAGA  
187 
                |||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||| 
Sbjct  1665323  TACAGTAATTGATTTTAAAACCAGTCATAACTTAGTGACTAAGAAACTTGATGTTAGAGA  
1665382 
 
Query  188      TGCTAGAGATTTTTTTATTAACTCCGAAATGGATGAATATGCAGCCAATGATTTTAAAGA  
247 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1665383  TGCTAGAGATTTTTTTATTAACTCCGAAATGGATGAATATGCAGCCAATGATTTTAAAGA  
1665442 
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Query  248      TGGARATAAAATAGCTATGTTCTCCGTCCCATTTGATTGGAACTACTTGTCAGAAGGAAA  
307 
                |||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1665443  TGGAGATAAAATAGCTATGTTCTCCGTCCCATTTGATTGGAACTACTTGTCAGAAGGAAA  
1665502 
 
Query  308      AGTCATAGCATATACCTATGGCGGAATGACSCCTTATCAA  347 
                ||||||||||||||||||||| |||||||| ||||||||| 
Sbjct  1665503  AGTCATAGCATATACCTATGGTGGAATGACGCCTTATCAA  1665542 
 
 
 
 
 
 
 
 
 
